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ABSTRACT

Plasmodium falciparum is a human intracellular parasite that is the causative
agent of a deadly form of malaria. This species alone is responsible for 200 million
cases of malaria annually resulting in over 1 million deaths worldwide. The excessive
mortality due to P. falciparum infection is due to its ability to cause severe pathogenesis
through hyperparasitemia and cytoadherence defined as the ability of infected red blood
cells to adhere to host vasculature. Cytoadherence is mediated through the export of
parasite proteins to the surface of the infected red blood cell (RBC). Exported proteins
have been identified but the pathway for protein export is still being elucidated.
Many protein coding genes in the P. falciparum genome are hypothetical and
therefore still need to be studied. Random transposon mutagenesis using the piggyBac
transposable element in P. falciparum has given us a library of mutants to use for
forward genetic studies. In this work, we describe a novel approach for screening P.
falciparum piggyBac mutants to look for differences in cytoadherence. We utilized an
image-based approach in order to quantify cytoadherence in P. falciparum NF54 wildtype and thirty-four piggyBac mutants. We found cytoadherence to be affected by the
expression of genes with specific gene ontologies including nucleic acid metabolism
and post-translational modification. Many of these genes are annotated as hypothetical
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or putative and this work may result in further revelations of a role for these genes in
parasite pathogenesis.
We further characterized a piggyBac mutant that was increased in cytoadherent
abilities as an atypical mitogen-activated protein kinase phosphatase (MKP) named
PfMKP1. We were able to demonstrate phosphatase activity in a generic substratebased assay and identify a putative substrate as mitogen-activated protein kinase 1
(Pfmap1). Furthermore, we found Pfmap1 to be differentially phosphorylated and a
difference in localization (through immunofluorescence assay) in the PfMKP1 mutant
line compared to the wild-type and complemented mutant. This adds to the recent work
characterizing this gene as important in cell cycle progression within the erythrocytic
cycle and lends to the hypothesis of a functioning mitogen-activated protein kinase
(MAPK) pathway in P. falciparum for which it is currently unknown.
Supplementary work focused on the development of tools to further investigate
the MAPK pathway and the role for PfMKP1 as an atypical MKP of Pfmap1 in this
pathway. A mass spectrometry-based technique was developed to look at Pfmap1 and
its potential active state based on its phosphorylation status. This approach needs
further development but the methods are described here within. In addition, the tools
needed to further characterize the binding interaction between PfMKP1 and Pfmap1
were established. The mass spectrometry screen and immunofluorescence screening
of Pfmap1 can further our knowledge of the MAPK pathway in P. falciparum and lead to
the identification of external stimuli that can induce growth or stress response in the
parasite. Taken together, the elucidation of mechanisms for cytoadherence and signal
transduction pathways in the parasite can lead to new drug target identification.
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CHAPTER ONE:
INTRODUCTION

Background
Malaria is one of the oldest diseases known to man, and yet it still causes more
than 200 million cases annually resulting in over 1 million deaths worldwide (51). The
causative agent of malaria is a group of apicomplexan parasites in the genus
Plasmodium. Plasmodium contains many species that cause disease in a range of
animals from reptiles, to birds, to mammals including rodents, non-human primates, and
humans. Five species are known to cause human malaria including P. falciparum, P.
vivax, P. ovale, P. malariae, and P. knowlesi which is a zoonotic infection (51). Of these
five species, P. falciparum and P. vivax cause the highest morbidity worldwide while P.
falciparum is responsible for the highest amount of mortality (2, 51, 89). P. falciparum is
mostly found in sub-Saharan Africa where children under the age of five and pregnant
women are most likely to succumb to the disease (51). Malaria is both preventable and
curable but further research into the biology of the parasite is paramount for the
development of new drug treatments and vaccine development.
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Parasite Life Cycle
The life cycle of the Plasmodium parasite is complex and involves both an
arthropod definitive host and a human intermediate host (Fig. 1.1) (1). Malaria infection
is initiated by the bite of an infected female Anopheles mosquito which injects
sporozoites into the bloodstream during a blood meal. The sporozoites find their way to
the host’s liver where they invade the sinusoidal layer and eventually a hepatocyte to
complete the exo-erythrocytic cycle. Once in the hepatocyte, the sporozoite matures
into a very large form called a liver schizont.

The schizont bursts and releases

thousands of merozoites into the bloodstream.

The merozoites go on to invade

erythrocytes where they begin rapid asexual reproduction in the erythrocytic cycle.
Within the erythrocyte, the merozoite undergoes a period of growth before DNA
replication and schizogony occurs. During schizogony, a schizont segments into a large
number of merozoites which eventually burst the cell and are released into the
bloodstream. After reinvasion into an erythrocyte, the individual parasites choose to
either undergo another round of asexual reproduction or to differentiate into a presexual form called the gametocyte. The default pathway is to continue the erythrocytic
cycle building up increased parasitemia in the host. For P. falciparum, the life cycle in
the erythrocyte is approximately 48 hours. The asexual reproduction within erythrocytes
is the pathogenic stage in the human host and will be the focus of this work.
If the sexual pathway is turned on, a gametocyte is formed which undergoes
stages of maturity within the human host. During these stages, gametocytes have been
found to sequester in bone marrow (10) however, by the time they reach full maturity,
gametocytes can be found in peripheral blood smears indicating that they can be
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ingested by another Anopheles mosquito taking a blood meal. Once in the mosquito
the gametocyte undergoes further maturation into a micro- or a macrogamete. The
microgamete exflagellates within the midgut of the mosquito and enters the
macrogamete forming a zygote. The zygote further differentiates into an ookinete and
enters the midgut of the mosquito where it develops into an oocyst.

The oocyst

ruptures to release sporozoites which travel to the salivary gland of the mosquito where
they are available to infect another human host when the mosquito takes another blood
meal. The sexual reproductive pathway is important in transmission of malaria.

Uncomplicated Malaria
Most patients infected with the malaria parasites will not show any visible signs
or symptoms. The disease state of malaria is caused by asexual reproduction of the
parasite in the erythrocytes of the host. There the parasites undergo the erythrocytic
cycle during which they degrade and burst red blood cells (RBCs). A characteristic
relapsing fever or paroxysm is apparent in the host as the immune system mounts a
response when schizonts burst RBCs to release the newly formed merozoites (74). The
loss of RBCs due to the parasitism of the host cell causes general malaise and can lead
to anemia (3, 57). In addition, the high turnover rate of the RBCs within the body leads
to liver and spleen enlargement (129).

Once the parasites are cleared from the

bloodstream by either drug treatment or the immune system, the host can fully
convalesce with the exception of P. vivax and P. ovale which can cause a relapse in
disease years after the initial infection.
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Severe Malaria
Plasmodium falciparum continues to cause significant mortality in developing
countries (51). It causes the most deaths of the five Plasmodium sp. due to its ability to
cause a severe form of malaria. The severity is due to its rapid growth cycle and ability
to cytoadhere. P. falciparum cases have the highest average parasitemia rate in the
blood (10-100x that of the other species). This high parasitemia contributes to severe
fever paroxysms and anemia both of which can cause death (110). In addition, the
ability of the parasite to adhere to host vasculature in either the brain or in the placenta
during pregnancy can cause cerebral or placental malaria. Placental malaria can cause
significant mortality to the mother and unborn child (110). Cerebral malaria develops
quickly and can cause death rapidly if untreated (62). Cerebral malaria leads to
seizures, coma and death in 30% of cases (110). In children, a diagnosis of cerebral
malaria indicates a poor prognosis indicating death or life-long sequela (110).

Diagnosis, Treatment, and Prevention
The gold standard for diagnosis of malaria remains to be microscopic evaluation
of a blood smear and visual identification of the species of parasite (1).

Other

diagnostics have come into use such as a molecular diagnosis using nested-PCR to
determine the specific species of infection (109) or immunofluorescence assay in blood
donations (115). However, in rural clinics in resource poor countries; these methods
are not viable options and diagnosis is made by symptoms alone during clinical
observation of the patient (27). This leads to misdiagnosis and incorrect distribution of
anti-malarial drugs.
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Anti-malarial drugs are recommended for the treatment of malaria. Anti-malarials
that were once commonly used to treat malaria are now ineffective due to drug
resistance in parasites (27).

Currently, artemisinin combination therapy (ACT) is

recommended by the World Health Organization for the treatment of malaria. To date,
only one radical cure is currently being utilized in the clinical setting, the 8aminoquinolone primaquine but this compound exhibits high toxicity in persons with
G6PD deficiency and is therefore not used for causal prophylaxis in P. falciparum
infections. In cases of severe malaria, oral drugs are not fast-acting enough and drugs
must be given intravenously. Current treatment of severe malaria is the intravenous
application of artesunate (1).
Malaria is a mostly preventable infectious disease. Prevention for non-immune
travelers visiting endemic areas is typically a course of anti-malarials such as malarone,
mefloquine, or chloroquine as well as the antibiotic doxycycline which is commonly used
(1).

However, the majority of anti-malarial prophylactics are contraindicated for

pregnant women and children. In addition, prophylactics are not a viable option for
those living in malaria endemic regions. Currently, there is no vaccine approved for the
prevention of malaria and those living in endemic countries can only utilize vector
control methods, such as the widespread use of bed nets and insecticides.

Vaccine Development
A vaccine for the prevention of malaria is currently the holy grail of malaria
eradication. Recently, one vaccine candidate has undergone phase III clinical trials, the
RTS,S subunit vaccine. This vaccine utilizes a parasite antigen, the circumsporozoite
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protein (CSP) Repeat region and T-cell epitope fused to the hepatitis B Surface antigen
and mixed with free hepatitis B Surface antigen hence the name RTS,S. The hepatitis
B portion is dual in purpose in that it acts as a stimulant to the immune system for the
malaria protein and also immunizes against hepatitis B.

In phase III trials, African

infants and children were administered the vaccine and followed for a period of time.
The children who received the vaccine were less likely to contract clinical and severe
malaria however the efficacy of the vaccine was low, 50% for clinical malaria and less
than 50% for severe malaria (9). The vaccine had less efficacy in trials of infants with a
30% protective level for clinical malaria and less than 30% for severe malaria (8).
Additional vaccine candidates are actively being pursued in pre-clinical and
phase I clinical studies (112). Both subunit and whole organism antigens are being
investigated including a duffy-binding protein (DBP) for P. vivax and an inactivated
sporozoite vaccine for P. falciparum [8].

These vaccines mostly target sporozoite

surface antigens aimed at reducing infection before the sporozoite can invade the host’s
liver (112). However, blood stage antigens and gametocyte antigens are also being
targeted to prevent disease and transmission, respectively.

Drug Resistance and Discovery
Malaria drug resistance is best described for P. falciparum as it is the most
deadly infection and treatment is imperative for survival.

Chloroquine-resistant P.

falciparum is the most widespread form but combination antifolate, mefloquine, and
atovoquone resistance have also emerged (27). The molecular basis for chloroquine,
antifolate combination drugs, and atovaquone resistance has been well established.
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Mutations in the target enzymes of these drugs allow for the parasite to become
resistant by a number of mechanisms including increased efflux ability or inability to
inhibit enzyme.
Because of drug resistance, the need for new drug development is high. Many
pathways have been targeted due to their uniqueness in the parasite including
hemoglobin digestion and the folate pathway. Mitochondrial function and respiration are
also high value targets since the electron transport chain in Apicomplexa species differs
from that of the mammalian host mitochondria.

However, there are other parasite

pathways that have yet to be explored for drug discovery.
Currently, an area of focus for P. falciparum drug development is kinase
inhibitors (30, 131). With the success of kinase inhibitors as treatment for other disease
models, much research is now being conducted to develop kinase inhibitors specifically
targeting P. falciparum kinase activity. Putative kinases and signaling pathways in P.
falciparum have been identified through bioinformatic analysis (14, 127). Many kinases
have been found to be divergent from mammalian kinases which may indicate their
usefulness as a drug target, including kinases that directly affect P. falciparum growth
and reproduction within the host (33, 43, 58). Recent advances in malaria research in
fields such forward genetics and structure activity relationship chemistry allow for
designer drugs which can target specific enzymes unique to P. falciparum.
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Plasmodium falciparum Biology and Pathogenesis

Cytoadherence
P. falciparum is the only human malaria species known to cause severe disease
in the form of cerebral malaria. There are two non-exclusive hypotheses for the cause
of cerebral malaria: 1) the P. falciparum-infected red blood cells (iRBCs) bind to host
endothelial cells and other RBCs which physically block the blood vessels leading to
vascular occlusion (12, 88); and 2) the iRBCs interact with host cells (endothelial or
platelet) causing activation of the endothelial cells and engagement of the immune
response that includes inflammation of the endothelial leading to blockage of the vessel
(49).

The mechanism for both hypotheses involves the iRBC receptor-mediated

attachment to host cells known as cytoadherence (120).
Cytoadherence of the host endothelial cells involves host cell receptors that allow
for P. falciparum derived proteins on the surface of the iRBC to bind. The endothelial
receptors indicated in cerebral malaria are most notably CD36 and ICAM-1 (21, 52, 92,
94). However, the ability of the iRBC to bind to these receptors alone is not sufficient
for cerebral malaria to occur. Recently, a study linked CD36 adhesion of iRBCs to
recruitment of integrin which further strengthened the cytoadhesion demonstrating how
the first step in cerebral malaria may be cytoadhesion of iRBCs but a more complex
system is necessary for disease (37).
On a molecular level, cytoadherence is caused by the export of parasite proteins
to the RBC surface which then interact with receptors on the surface of host cells such
as CD36, ICAM-1, VCAM, CSA and others. P. falciparum makes and exports proteins

8

to the surface of the iRBC that are responsible for this interaction, most notably
erythrocyte membrane protein 1 (PfEMP1). It is clear that PfEMP1 is surface expressed
and critical for binding to host cell receptors (26, 77, 82).

Other proteins directly

involved in the surface exposure of PfEMP1 such as PfEMP3 and KAHRP are also
known to affect cytoadherence (103, 125).

Many other proteins and organelle

structures such as Maurer’s clefts that are vital to the expression and localization of
these proteins are expressed and exported to the RBC cytoplasm by P. falciparum.
Reports have been able to highlight the effects of some proteins but a clear picture of all
the proteins involved in protein exportation to the RBC is still widely unknown due to the
complexity of the system.
Knob structures.

Knob structures are electron-dense protrusions on the

surface of the iRBC that contain proteins of parasite origin (11). Knobs form as the
parasite matures in the RBC (75).

Within the knobs, knob-associated histidine-rich

protein (KAHRP), PfEMP1, and PfEMP3 interact and allow for the display of the variant
PfEMP1 molecules on the surface of the RBC membrane. Studies suggest that these
structures play a role in increasing rigidity of the RBC due to their interaction with actin
and spectrin in the RBC cytoskeleton (83).

Knob structures are directly implicated in

the ability of the parasite to cytoadhere and the type of PfEMP1 that is expressed on the
surface is responsible for the specificity of the adherence to host cell receptors such as
CD36 (36).
Exported proteins. P. falciparum exports a large repertoire of proteins during its
development within the RBC including those in the knob structures. There are 2
mechanisms for protein export, Plasmodium export element (PEXEL)-dependent and
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PEXEL-independent. The parasite export pathway is complex, utilizing parasite-derived
organelles in the RBC cytosol (Maurer’s clefts) and multiple export pathways (e.g.
PEXEL motifs and classical vesicle exportation) that extend beyond the confines of the
parasitophorous vacuole membrane (PVM) (28, 48). Exported proteins are thought to
follow the same initial path as found in other eukaryotic cells where the signal peptide is
targeted to the endoplasmic reticulum which utilizes a vesicle budding system to
translocate proteins across the cell membrane. Enzymes like phosphatidylinositol 3phosphate found in the endoplasmic reticulum, aspartic proteases, and plasmepsin V
play a role in the processing of PEXEL-motif proteins; however, these enzymes are not
solely responsible for the export of parasite proteins (25, 29, 104).
Once proteins are packaged for export, they must be translocated across the
plasma membrane (PM) and PVM into the RBC cytosol and beyond. Proteins with a
hydrophobic signal sequence followed by a PEXEL/HT motif, including KAHRP and
PfEMP3, are exported to the RBC cytosol via a PTEX translocon in the PVM (38).
Although PfEMP1 has a PEXEL motif, it lacks the hydrophobic sequence and there is
no cleavage of the PEXEL motif to the mature N-terminus sequence which allows for
exportation of PEXEL proteins (108). Therefore, PfEMP1 is thought to represent a nonPEXEL protein in its path of exportation (86). Non-PEXEL exported proteins that
contain a transmembrane domain are exported to the Maurer’s clefts in the RBC cytosol
(13, 106) after passage through the parasite membrane and PVM as an unfolded
protein (59). Other proteins involved in this exportation pathway are still being
determined, including the translocons responsible for non-PEXEL export out of the PV.
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Changes to the rigidity and deformability of the RBC occur when the parasite
develops within the RBC, which in turn affects cytoadhesion of the iRBC and iRBC
sequestration (117). Some exported parasite proteins affect cytoadherence by changing
the RBC cytoskeleton (84). PHIST proteins are a group of exported proteins within the
Plasmodium helical interspersed subtelomeric family that are expanded to 72 paralogs
in P. falciparum (105). PHIST proteins stabilize proteins present in the electron-dense
knobs of mature-parasite iRBCs responsible for cytoadherence as well as interact with
RBC cytoskeleton to affect rigidity (85, 95).
P. falciparum erythrocyte membrane protein 1 (PfEMP1).

PfEMP1 is an

exported parasite protein found on the surface of infected RBCs. PfEMP1 is made early
on in the parasite life cycle and is exported as the parasite matures. There are 60 var
genes that code for 60 different PfEMP1 molecules in P. falciparum. These genes are
monoallelic in expression meaning only one type of PfEMP1 molecule is found on the
surface of an infected RBC (107). Their expression is under tight control where 59 of
the 60 genes are being actively repressed and only one gene is being actively
transcribed (64). The expressed PfEMP1 molecule that is composed of several
domains: the acid-terminal sequence (ATS) which is known to interact with KAHRP
within the RBC, and the variable domains such as the cysteine-rich interdomain region
(CIDR) and the duffy-binding like (DBL) domain which are responsible for the specificity
of PfEMP1 binding to host cell receptors (76, 85, 122). Although only one PfEMP1
molecule is expressed at a given time, antigenic switching can occur where the parasite
within the human host or within culture can switch the PfEMP1 being expressed which
can change cytoadherent properties of the cell.
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PfEMP1 is exported into the RBC cytosol during infection. It contains a PEXEL
motif however it lacks the hydrophobic sequence that is necessary for PEXEL protein
trafficking to the RBC cytosol and is therefore thought to be transported to the RBC
through a different mechanism than PEXEL proteins such as KAHRP (69, 87, 111). As
of yet, the translocon that transports PfEMP1 across the PVM is not known. However, it
is known that PfEMP1 interacts with Maurer’s clefts where it assembles with the other
knob associated proteins before it reaches its final destination at the surface of the RBC
within the knob structures (93).

Signaling Pathways in Plasmodium falciparum
Signaling pathways allow cells to respond to external stimuli by regulating cellular
processes (23). In P. falciparum, signaling pathways are involved in cell cycle control,
sexual differentiation, and pathogenic mechanisms such as host cell invasion and
cytoadherence. Specifically, calcium-dependent mechanisms for signaling have been
implicated in invasion (67, 119) and phosphatidylinositol-dependent signaling has been
found to be involved in hemoglobin digestion within the parasite (118). Other signaling
pathways based on phosphorylation cascades are currently being studied and are found
to have significant cellular affects even though the mechanisms and entire pathways
remain unclear.
Since the late 1970s, researchers have been investigating global phosphorylation
dynamics of erythrocytes infected with Plasmodium sp. (34, 66, 90, 114, 128). These
first studies demonstrated the importance of phosphorylation pathways in Plasmodium
infections and laid the ground work for future global phosphorylation studies. Based on
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these pre-mass spectrometry era proteomic studies, three major insights into
phosphorylation patterns in Plasmodium species during the erythrocytic life cycle were
discovered.

One, the state of phosphorylation is dependent on the stage of

Plasmodium and changes over the course of the 48 hour life cycle (114, 128). Two, the
parasite causes reversible changes in the phosphorylation of the RBC proteins during
invasion and infection (90). Three, phosphoproteins are species dependent (128).

P. falciparum kinome and phosphatome.

Bioinformatic analyses of the P.

falciparum genome identified kinases belonging to all major eukaryotic kinase families,
with the exception of tyrosine kinases and STE (STErile yeast) kinases (14, 124). In
these studies, 65 typical eukaryotic protein kinases (ePKs) and 99 protein kinase-like
sequences were identified. The atypical ePKs that were found are thought to be a
previously unknown group of kinases that may be unique to Apicomplexan. Because of
their unknown function, these kinases are deemed “orphan” kinases (41). Even kinases
that have shown significant homology to other ePKs are divergent to the point where the
substrate and function in P. falciparum is still unknown.
Phosphatases have also been elucidated through bioinformatic analysis of the P.
falciparum genome. Wilkes and Doerig identified 34 putative phosphatase sequences
in P. falciparum which encode for phosphatases in all known groups of eukaryotic
protein phosphatases and additional non-protein phosphatase groups (127). However,
certain protein sequences containing phosphatase domains were not identified in this
study and therefore this study may reflect only a partial true Plasmodium phosphatome.
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Signaling pathways and cell cycle control. It is controversial whether the
Plasmodium erythrocytic cell cycle follows that of a typical eukaryote, i.e. distinct G1, S,
G2, M phases (14, 16, 40). However, the P. falciparum cell cycle is thought to be
regulated by cyclin-dependent kinases (CDKs) in a similar manner to other eukaryotes.
Evidence for this includes the fact that phosphorylation of proteins changes as the cell
cycle progresses and specifically tyrosine phosphorylation which may play a major role
in cell cycle development (96).

There are six CDK-related kinases identified in P.

falciparum and 45 putative phosphoproteins substrates for the CDKs (96). Two CDKs
have been identified as localized in the nucleus where they can affect transcription and
are critical in the asexual life cycle (7). The P. falciparum CDK Pfmrk has greatest
homology to human CDK7 and has been shown to form a complex with effector
molecules (Pfcyc-1 and PfMAT-1) in the same way that CDK7 does in its active state
(65). Pfmrk is of current investigation as a novel drug target (24, 54, 97).
Other enzymes have been implicated in cell cycle control through genetic
manipulation.

Attempts to knock out function of certain kinases within erythrocytic

culture have failed. For example, the inability to inactivate both Pfmap-2 and Pfcrk1
suggests their essentiality in erythrocytic schizogony (43, 68, 99) although their direct
target and pathway is still unknown. Recently, phosphatases have also demonstrated
importance in cell cycle control.

A putative mitogen-activated protein kinase

phosphatase PfMKP1 was found to be involved in cell cycle control where the loss of
expression of this phosphatase led to the delay of entry into the DNA synthesis phase
(18) demonstrating a critical role for progression in the cell cycle. Another phosphatase
was identified as causing a block in the G2/M phase which may indicate its role in
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regulating the cell cycle of the parasite (121). Taken together, enzymes involved in
signal transduction are critical for proper timing and regulation of the Plasmodium cell
cycle in its erythrocytic stages.
Signaling pathways and host cell adaptation. During the erythrocytic cycle in
the host, P. falciparum invades the RBC, reorganizes the host cell, and exports its
proteins to the RBC and extracellular environment in order to survive. For a merozoite
to invade a RBC, two events must occur; the reorganization of the RBC cytoskeleton
and the formation of the parasite invasion machinery, the glideosome complex (22, 39,
98). After the merozoite invades the RBC, it continues to modify the host environment
through protein export (described above).

Exported proteins include kinases,

phosphatases, and phosphoproteins of parasite origin.
First, a rearrangement of the erythrocyte cytoskeleton must occur such that it
increases the permeability of the cell. During this process both erythrocytic and parasite
proteins undergo differential phosphorylation (90). In an uninfected RBC, band 4.1
associates with spectrin lending to the structural integrity of the RBC and β-spectrin
contributes to the overall stability of the RBC cytoskeleton (53). When an RBC comes
into contact with a P. falciparum merozoite, both band 4.1 and β-spectrin are
phosphorylated, which reduces cytoskeleton association and stability (35, 47). Other
RBC proteins such as ankyrin and actin may also be modified and lead to increased
susceptibility of the host cell to the invading merozoite (126). After invasion, parasite
phosphoproteins can interact with both band 4.1 and spectrin, namely MESA and
KAHRP, to further stabilize the host cell and allow for protein trafficking.
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Secondly, to invade the RBC, the merozoite must form the necessary invasion
machinery.

This invasion machinery is referred to as the glideosome complex in

Apicomplexan parasites.

The glideosome forms through the phosphorylation-

dependent association of PfGAP45, PfGAP50, PfMyoA, and PfMTIP in the outer
membrane of the parasite [66,71,(56).

Specifically, PfGAP45 post-translational

modification is necessary for this formation and has shown to be at least partially
dependent on serine/threonine kinase activity (67).

Furthermore, both PfGAP45 and

MTIP have been shown to be phosphorylated by CDPK1 (56) but the function of this
phosphorylation is not yet known. Therefore, phosphorylation events are critical for the
parasite entry into the RBC where it can survive and reproduce as an intracellular
parasite.
During infection by P. falciparum, the RBC undergoes phosphorylation patterns
different than that of an uninfected cell which may play a role in intracellular survival of
the parasite and pathogenesis. Phosphorylation has been implicated in cytoadherence
in many studies but its exact role has not been elucidated (60, 61, 81, 130).
Specifically, reports have demonstrated that proteins associated with this interaction are
phosphorylated during the adherence such as RBC protein CD36 (60), and parasite
proteins PfEMP1 and KAHRP (81). In addition the interaction of KAHRP with spectrin in
the RBC cytoplasm has been shown to be phosphorylation dependent. At least one
kinase was implicated in this process, casein kinase II, for its role in phosphorylation of
PfEMP1 (61). Recent studies have attempted to analyze the differential regulation of
phosphorylation in strains with different cytoadherent properties but have failed to find a
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direct connection (130). Other exported proteins are involved in phosphorylation and
host cell remodeling such as the PHIST and FIKK kinase family as mentioned above.

Mitogen-Activated Protein Kinase Pathway
The mitogen activated protein kinase (MAPK) pathway is found in eukaryotic
cells and allows a cell to sense its external environment and respond to stimuli. The
MAPK pathway is responsible for many cellular changes within the cell such as
proliferation, differentiation, growth, and adhesion (32). The MAPK pathway utilizes a
phosphorylation cascade to transmit external stimuli through a cell to affect transcription
and expression of proteins within the cell. In this pathway, there is a tiered level of
kinases where a membrane-bound tyrosine kinase receptor (ex. Insulin receptor or
EGRF) recognizes the initial external signal and transmits it across the cell membrane
to a MAPK kinase kinase (MAPKKK), which phosphorylates a MAPK kinase (MAPKK),
and in turn phosphorylates a MAPK. MAPKs are phosphorylated within their active
pocket on the conserved motif TXY where both the Thr and the Tyr need to be
phosphorylated in order to activate the kinase. If a MAPK auto-phosphorylates the Tyr
without the activation of the MAPKK, off-target substrates may be phosphorylated.
When a MAPK is properly activated, it is shuttled into the nucleus where it interacts with
transcription factors to change transcription within a cell. A MAPK can be deactivated
through dephosphorylation of the TXY motif dependent on a MAPK phosphatase (MKP)
in either the cytoplasm or nucleus of a cell.
The MAPK pathway has been identified in eukaryotes from yeast to humans and
is thought to originate from a common progenitor cell (32). Currently, the existence of
17

the MAPK pathway in parasitic protozoan is debated however homologues to MAPK
proteins are present in all species (Table 1.1). In addition, the predicted effects of the
MAPK pathway exist in mutant parasite lines where MAPK homologues are knocked
out. Human parasites from the order Kinetoplastida have large MAPK repertoires such
as Leishmania and Trypanosoma. Apicomplexan parasites such as Toxoplasma gondii
and Cryptosporidium parvum (not shown (17) possess three MAPK homologues while
P. falciparum has only two identified MAPKs. Other proteins in the pathway are putative
and more work is needed to definitively place them in the MAPK pathway, ex. PfYVH1
(Table 1.1).

P. falciparum MAPK Pathway
In P. falciparum, the lack of tyrosine and STE kinases has led to the conclusion
that the MAPK pathway is not fully functioning in the parasite (123). However, there are
other kinases in the P. falciparum genome that can act as regulators of MAPKs (Table
2). In vitro studies have suggested that Pfnek kinases can act as MAPKKs to activate
MAPKs and the presence of PfTKLs (tyrosine kinase-like) kinases indicate their
potential role as MAPKKKs. To date, there is still no receptor protein that has been
identified as able to transduce the signal across the parasite membrane but more study
is needed in this area. The two MAPKs in the genome have been characterized and
are described in the next section.

P. falciparum has 2 genes indicative of MAPK

phosphatases (MKPs) and recently a third has been described (18).
P. falciparum MAPKs.

Both MAPKs in the P. falciparum genome are

considered atypical due to their divergent sequences but both kinases retain kinase
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activity (43, 55). Pfmap1 has a typical kinase domain with the canonical TXY motif
however there is a large c-terminal extension characterized by acidic residues (42, 55,
78). Pfmap2 is atypical in that it does not resemble a MAPK and does not have the
TXY motif (45). Instead it contains a TSH motif that has been shown to be critical for its
activity where the Thr residue can be phosphorylated by Pfnek-1 and Pfnek-3 in order to
activate the enzyme (46, 79). Pfmap2 is a low expressing protein but has been shown
to be critical for erythrocytic growth in P. falciparum and essential for male
gametogenesis in P. berghei (43, 100, 116). The function of Pfmap1 is still elusive as it
can be knocked out in blood-stage culture with no observable phenotype (43). There
are also no known kinase activators of Pfmap1 as those tested so far have shown
specificity to Pfmap2 (79, 80).
Pfmap2 is implicated in gametocytogenesis and is thought to be part of a
signaling pathway that is stimulated by environmental changes that occur when the
parasite moves from the human host to the mosquito including temperature change and
the presence of xanthurenic acid (72). Both of these signals are thought to stimulate
phosphoinositol or cGMP pathways that activate an upstream calcium-dependent
protein kinase (CDPK4) which may in turn activate Pfmap2 in order for exflagellation to
occur. This proposed pathway is a hint to the presence of the MAPK pathway but
shows that it may interact with other pathways and itself be incomplete in P. falciparum.
P. falciparum MKPs.

P. falciparum has two identified MKPs in its genome

which are classified as type I due to the presence of a single dual-specificity
phosphatase (DUSP) domain (Fig. 1.2). Only one of these phosphatases has been
studied.

PfYVH1 was shown to have zinc-dependent phosphatase activity and the
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ability to translocate between the nucleus and cytoplasm of the parasite where it can
interact with other proteins in the nucleus (Table 1.2) (73).

These characteristics

coincide with those of known MKPs in other organisms although PfYVH1 has not yet
been studied in the context of this pathway. Recently, another putative phosphatase
was identified as a MKP matching the type II domain structure (Fig. 1.2) where there is
an inactive rhodanese domain followed by a DUSP domain in tandem (18). In type II
MKPs, the inactive rhodanese domain can act as a MAPK binding domain (MKB) if it
contains a signature kinase interaction motif (31). PfMKP1 was shown to play a role in
cell cycle regulation where it was critical for progression of the parasite into the DNA
synthesis phase (18). This function is in alignment with the function of MAPK pathways
in other organisms and indicates that a functioning MAPK pathway may exist in P.
falciparum.

Genetic Manipulation of P. falciparum
Techniques for genetic manipulation of Plasmodium falciparum remain tedious
and unreliable. Double homologous recombination is the standard technique used in
reverse genetic studies (70, 71). However, some genes are not amenable to genetic
ablation and therefore cannot be studied in this method (43). Advances have been
made in the genetic manipulation of P. falciparum including the use of zinc-finger
nucleases and other site-specific integration techniques; however, the relative cost of
these methods is high and the methods are still time consuming as only one gene is
targeted (6, 113). Recently, protein destabilization domains have been utilized to study
genes thought to be essential to the parasite life cycle (15).
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An alternative to P. falciparum genetic manipulation is to use P. berghei as a
surrogate due to its ease in genetic manipulation. However, some important biological
distinctions remain between P. falciparum and P. berghei. For example, P. falciparum
contains proteins to which there is no homologue found in P. berghei (PlasmoDB). In
addition, there is an expansion of certain protein families in P. falciparum that may be
linked to the pathogenesis of the organism. For example, the FIKK family of kinases
are largely expanded in P. falciparum compared to P. berghei and are actively exported
to the RBC cytosol where they may affect cytoadherence (91). Other proteins and
pathways may differ due to the biology of the host for which each species is specifically
suited for (43, 116).

piggyBac Random Transposon Mutagenesis
Random transposon mutagenesis is a quick and efficient way to make a library of
mutant lines that ideally saturate the genome and allow for identification of essential
genes.

This technique has successfully been applied in P. falciparum where the

piggyBac transposable element was used to create a library of genetic mutants from the
wild type NF54 strain (19).

These mutant parasite lines allow for screening in

phenotypic studies to assign functions to genes that have only hypothetical or putative
protein status. Previously, piggyBac mutant libraries have been used to identify genes
critical to intra-erythrocytic growth and to gametogenesis (20, 63).

In this work, we

continue to screen a P. falciparum piggyBac mutant library for novel phenotypes leading
to the elucidation of the function of unidentified genes.
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Goals of Current Work
The goals of the work presented here within were to develop a scalable screen
for the phenotypic study of a piggyBac generated P. falciparum mutant library to look for
genes involved in cytoadherence of the parasite.

In addition, PfMKP1, which was

initially identified through the piggyBac random mutagenesis project and categorized as
an atypical-MAPK phosphatase, was further characterized for catalytic activity and
substrate specificity.

Lastly, to continue the study of the MAPK pathway in P.

falciparum and look for stimuli of this pathway, a multiple reaction monitoring assay was
developed for future implementation.
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Figure 1.1: Life Cycle of Plasmodium Species. An Anopheles mosquito is the vector
for Plasmodium infections. The erythrocytic cycle (B) is the pathogenic stage in the
host and the focus of this work.
Figure taken from http://www.cdc.gov/dpdx/malaria/index.html.
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Table 1.1: Mitogen Activated Protein Kinase (MAPK) Proteins in Representative
Parasitic Protozoan.
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Table 1.2: Putative Enzymes in the MAPK Pathway in P. falciparum.

Gene name
Pfnek-3
Pfnek-1
PfTKL-1

PlasmoDB ID
PF3D7_1201600
PF3D7_1228300
PF3D7_0211700

In vitro activity
phosphorylation
phosphorylation
ND

Putative role in
MAPK pathway
MAPKK
MAPKK
TGFβ receptor

Putative
substrate
Pfmap2
Pfmap2
ND

PfTKL-2
PfTKL-3
PfTKL-4
Pfmap1

PF3D7_1121300
PF3D7_1349300
PF3D7_0623800
PF3D7_1431500

phosphorylation
phosphorylation
ND
phosphorylation

unknown
MAPKKK
MAPKKK
MAPK

ND
ND
ND
ND

Pfmap2
PfYVH1
PF3D7_020310
0
PF3D7_145510
0

PF3D7_1113900
PF3D7_0309000

phosphorylation
dephosphorylation

MAPK
MKP

ND
Pescadillo

Role in life cycle
asexual reproduction
asexual reproduction
ND
host
immunomodulatory
asexual growth
ND
ND
erythrocytic stages;
male gametogenesis
parasite development

PF3D7_0203100

ND

MAPKK

ND

ND

PF3D7_1455100

ND

MKP

ND

PfMKP1
PF3D7_110680
0
PF3D7_101300
0
Pfnek-2
PfNEK-4

PF3D7_1305500

dephosphorylation

MKP

Pfmap1

ND
protein export, cell
cycle

PF3D7_1106800

ND

Raf kinase

ND

ND

PF3D7_1013000
PF3D7_0525900
PF3D7_0719200

ND
phosphorylation
None

TNFR
ND
ND

ND
ND
ND

ND
sexual
sexual

PlasmoDB ID (PlasmoDB: a functional genomic database for malaria parasites; plasmodb.org/plasma; v.11.0)
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References
(80)
(44, 46)
(123)
(5)
(4, 14)
(14, 123)
(42, 55)
(44, 116)
(73)
(14)
(127)
This report
(18)
(14)
PlasmoDB*
(102)
(101)

Figure 1.2: Classification of MAPK Phosphatases (MKP). NT = N-Terminal domain,
MKB = MAPK Binding domain, DUSP = Dual-Specificity Phosphatase domain, PEST =
Proline, Glutamine (E), Serine, Threonine rich domain. Adapted from (50).
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CHAPTER TWO:
A SCALABLE PHENOTYPIC SCREEN OF PIGGYBAC PLASMODIUM FLACIPARUM
MUTANTS REVEALS A ROLE FOR AN ATYPICAL MAPK PHOSPHATASE IN
CYTOADHERENCE

Introduction
Malaria is a deadly parasitic disease and is responsible for an estimated 660,000
deaths worldwide (1).

Of the 5 species that cause human malaria, Plasmodium

falciparum is responsible for almost all deaths due to severe malaria. The pathogenesis
of severe malaria involves severe anemia, pulmonary edema, and renal failure due to
high parasite loads in the blood and cerebral malaria due to parasite sequestration (see
review (48)). Parasite sequestration in tissues occurs through cytoadherence of the P.
falciparum-infected red blood cells (iRBC) to host endothelial cells, uninfected RBCs, or
platelets. This process is also important for evasion of splenic clearance and the
immune system which allows the parasite to survive undetected in the host (48).
To catalyze sequestration, the parasite exports a large number of proteins into
the RBC cytosol and onto the RBC surface. Some of the most well-studied exported
proteins, such as PfEMP1, PfEMP3 and KAHRP, form complexes at the RBC
membrane called knobs, structures that play a key role in sequestration (33). PfEMP1
protrudes from the knobs and is directly responsible for interacting with and adhering to

34

host cell receptors (e.g. CD36, ICAM-1, etc.); consequently when there is no PfEMP1
surface expression, cytoadherence is greatly diminished (26). KAHRP and PfEMP3 by
contrast do not contact host cell receptors directly, but form part of the knob structure.
Disruption of either gene reduces display of PfEMP1 at the knob surface and therefore
also affects cytoadherence (11, 40, 50).

A few proteins have been relatively well

characterized including the pathways that facilitate and control knob formation, such as
transcriptional regulation of exported proteins, protein export, and RBC cytoskeleton
rearrangement and stabilization.
In order for proteins to be effectively exported from the parasite to the RBC,
many processes must occur. First, the protein must be transcribed and expressed
during the ring stage ready for export during the later stages. Some exported proteins
are multiple gene families where transcription is tightly regulated, ex. var genes and
PfEMP1 proteins (43).

Second, the protein must be exported through the proper

channels in order to localize properly in the RBC cytosol, i.e. PEXEL vs non-PEXEL
translocation (7, 15). Thirdly, the protein must undergo post-translational modification
and/or be able to interact with partner proteins in the RBC cytosol to stabilize the newly
transformed host cytoskeleton, ex. PHIST proteins regulate cytoskeleton binding
through phosphorylation-dependent mechanisms (8, 36). While these steps are known
to be important for the export and stabilization of parasite proteins in the host, many
proteins critical for these interactions remain unknown.
Further exploration of the mechanisms involved in protein export and
cytoskeleton rearrangement of the RBC is important for drug discovery as this is a
unique attribute of the parasite and paramount for the parasite’s survival within the host.
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These mechanisms also contribute to cytoadherence which causes severe disease in
the host.

In this work, we have developed a scalable method for determining

cytoadherence to human receptor proteins (CD36) trans-expressed in Chinese Hamster
Ovary (CHO) cells. We applied this method to a library of P. falciparum mutants with
random piggyBac insertions in or near genes, many of which have no homologues in
other eukaryotes (5). The piggyBac system is a powerful tool to study gene function,
and this work represents its first application to the study of cytoadherence. The screen
identified several novel genes that impact cytoadherence, including an atypical MAPK
phosphatase where transposon insertion into the coding sequence, disrupting gene
function, conferred an increase in cytoadherence due to an increase in knobs on the
surface of the iRBCs.

Materials and Methods

Parasite Culture
Plasmodium falciparum NF54 piggyBac mutants were previously made in the
course of a whole genome random mutagenesis project (5). Briefly, mature blood-stage
parasites were purified on a MACS magnetic column (Miltenyi Biotec) and 1 million
purified parasites were added to erythrocytes loaded with 100 μg of a plasmid
containing the piggyBac transposon with human DHFR gene flanked with P. falciparum
UTRs and 50 μg of the transposase plasmid to start a 5 ml parasite culture. Individual
mutant clones were obtained by limiting dilution of parasites post-drug selection. All
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insertion sites were identified as described (5) (Table 2.1).

The complemented

piggyBac mutant (C9 complement) was made previously (4).
All cultures were maintained using standard techniques. Plasmodium falciparum
wild-type NF54 and the mutant clones were cultured according to standard methods at
37°C and gassing (5% O2 and 5% CO2, nitrogen balanced) with 5% hematocrit (O+
blood, Interstate Blood Bank) in RPMI 1640 medium (Invitrogen) supplemented with
0.5% Albumax II (Invitrogen), 0.25% sodium bicarbonate and 0.01 mg/ml gentamicin.
The complemented piggyBac mutant was maintained with 2 μg/ml Blastocidin-D to
maintain the episome. Parasite lines were kept in culture for no longer than 3 months
as to keep the integrity of the transposon insertion and minimize antigenic variation.
For assays, parasite lines were synchronized during ring stage a minimum of 2x using
5% sorbitol unless otherwise stated.

Chinese Hamster Ovary (CHO) Cell Culture
PsgA-745 Chinese hamster ovary (CHO745) cells deficient in glycosaminoglycans
(American Type Culture Collection) and CHO745 transfected with CD36-expressing
plasmid were gifts from Artur Scherf at the Institut Pasteur (19). All CHO cells were
cultured in accordance with ATCC recommendations using RPMI (with hypoxanthine
and HEPES) with 10% fetal calf serum and 1% Pen Strep (Gibco).

CHO Cell CD36 Expression
CHO cells were tested for the expression of CD36 receptor by western blot.
CHO cells were trypsinized (Trypsin-EDTA, Cellgro) in flask and resuspended in RPMI.
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Cells were counted with a hemocytometer and equalized to 1 x 105 cells/ml. Cells were
pelleted from 1 ml of suspension and resuspended in SDS-PAGE buffer with 100 mM
DTT. Lysates were run on a 10% SDS-PAGE gel and transferred to nitrocellulose.
After blocking for 1 hour in 5% skim milk, Rabbit anti-CD36 (Pierce Thermo Scientific)
1:1000 in PBS-Tween 20 and 5% skim milk was incubated with the blot overnight at 4°
C. The blot was washed 3x with PBS-Tween 20 and incubated with Goat anti-rabbit
HRP conjugated antibody (Jackson Laboratories) for 1 hour followed by washing with
PBS Tween 20 3x. ECL reagent (GE Healthcare) was added and the blot was imaged
on an x-ray developer (Konica Minolta SRX-101A).

Cytoadherence Assays
CHO745 and CHOCD36 cells were seeded into a 96-well plate 4 days prior to the
assay at 1 x 104 cells per well in CHO cell media in order to allow for adherence and
proper confluence. Media was changed every day until assay and plates were kept at
37°C with 5% CO2.
Parasite cultures were synchronized and grown to 2-5% parasitemia. Parasite
cultures were harvested in late trophozoites stages (24-30 p.i.) by gel flotation. Briefly,
RBCs were pelleted by centrifugation at 2426 x g for 3 min. Plasmagel (25 ml 1M
HEPES, 2 g CaCl2, 7.5g NaCl, 30g powdered gelatin, 900 ml di water) and RPMI was
added to the RBC pellet and the mixture was incubated at 37° C in a water bath for 20
min. After separation occurred, the top layer was removed and washed in RPMI. Cells
were counted on a hemocytometer and all cultures were adjusted to 1x107 cells/ml.
One hundred μl of suspension was added to each well of the seeded CHO cell plate.
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The plate with CHO cells and purified iRBCs was incubated at 37° C for 1 hour with
agitation every 15 minutes. The plate was then washed with RPMI a minimum of 5x
and fixed with 2% paraformaldehyde in RPMI for a minimum of 30 minute or overnight
at 4° C. After fixation, the plate was washed with PBS and the cells were stained with
10 μg/ml Hoechst 33342 and APC mouse anti-Human CD235a (BD Pharmingen)
1:4000 dilution in PBS for 20 minutes in the dark. For visualization of CD36, Rabbit
anti-CD36 was added at a 1:1000 dilution. The plate was washed 2x with PBS and left
in PBS for visualization.

Visualization and Counting of Cytoadherence Assays
After fixation and staining of cells, 96-well plates were imaged using the
Operetta® High Content Imaging System (PerkinElmer) in wide field fluorescence mode
using the 20X high NA objective. Twenty-five fields per well were imaged and analyzed.
A customized algorithm by Harmony® Software (Perkin Elmer) was used to count CHO
cell nuclei based on Hoechst 33342 staining and determine cytoplasmic area based on
nuclei staining (Fig. 2.1C-F). Only iRBCs within the border of the CHO cell cytoplasm
were counted and the output was in iRBC per CHO cell. The following equation was
used to define fold change in cytoadherence:
∆Fc = 3√((xCD36 – x745)/(wtCD36 – wt745)) -1
where x is the piggyBac mutant line being tested and wt is NF54 parental line.
Mutant lines were determined to be decreased or increased in cytoadherence if they
were statistically significantly different than the wild-type in a one-way ANOVA followed
by Dunnett’s multiple comparison test (GraphPad Software, La Jolla California USA).
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RNA Isolation, cDNA Synthesis, and Quantitative Reverse Transcription
(qRT)-PCR
RNA was isolated and purified using a TRIzol reagent and following
manufacturer’s directions (Invitrogen). First-strand cDNA was synthesized by random
primer mixes using Superscript III Reverse Transcriptase (Life Technologies) according
to the product manual. PCR primers used for detecting mRNA expression of var genes
were as described previously (41). qPCR was performed on a Stratagene Mx300P.
The relative standard curve method (ABI User Bulletin #2) was used where genomic
DNA was used in a standard curve to determine relative copy number and a
housekeeping gene seryl-tRNA synthetase (PF3D7_0717700) was used to normalize
the transcriptional level of each var gene.

P. falciparum PfMKP1 Antibody
Custom monoclonal antibodies to PfMKP1 were made by Abmart (Shanghai,
China). Briefly, peptide KNNENKQSSKNE was over-expressed in E.coli, and purified
by Ni-affinity chromatography. Three 8 to 12-week old BALB/C mice (female) were
immunized with the peptides and the mouse with the best immune response was
chosen for hybridoma production.

The mouse spleen cells were fused with SP2/0

myeloma cells to generate the hybridomas. This mixture of cells was then diluted and
clones were grown from single parent cells on microtiter wells in HAT medium. The
hybridoma clones, selected for their ability to bind antigen in an ELISA, were injected in
the peritoneal cavity of mice. After 10-14 days, ascites fluid from tumors were collected
and screened in western blot against mixed-stage parasite cultures.

40

P. falciparum Protein Extraction and Western Blot
Parasite culture was synchronized twice with 5% sorbitol and parasites were
harvested 5 hours later for ring stage and 28 hours later for trophozoites stage. All
parasites were harvested by incubating with PBS with 0.1% saponin in order to lyse
RBCs. Cells were washed 3x to remove RBC debris and the resulting parasite pellet
was resuspended in SDS-PAGE buffer.

For ring stage parasites, parasitemia was

equalized to 5% between cultures. For trophozoites stages, culture was harvested and
iRBCs were purified through MACS magnetic column (Miltenyi Biotec). The purified
iRBCs were counted by hemocytometer and adjusted to 1 x 10^7 cells/ml to standardize
the number of iRBC across strains.

Samples were loaded onto a gradient SDS-PAGE

gel and western blot was conducted in the same manner as stated above using Mouse
anti-PyBiP (a gift from Sebastian Mikolajczak, unpublished) at 1:1000 and Rabbit antiEXP2 (a gift from Paul Gilsen) at 1:5000 or anti-PfMKP1 at 1:1000. Secondary HRP
conjugated goat anti-rabbit or anti-mouse (Jackson Laboratories) was used at a
1:10,000 dilution.

Surface PfEMP1 Expression
Surface expression of PfEMP1 was determined using the methods of Spycher et
al. (45). Briefly, parasites were synchronized by sorbitol twice 4 hours apart, grown to
trophozoite stage (20–28 h post invasion) at a parasitemia of approximately 5%, and
harvested by magnet column (CS columns; Miltenyi Biotec). Infected RBCs were
equalized between strains to 1 x 10^7 cells and either treated with TPCK-treated trypsin
(Sigma) 1 mg/ml or incubated in PBS for 10 min at 37°C. The reaction was stopped with
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protease inhibitor cocktail (Invitrogen) and the sample was pelleted and solubilized in
1% Triton-X 100. The insoluble pellet was resuspended in 2% SDS buffer, loaded onto
a gradient Tris-Glycine gel and subjected to SDS-PAGE. The proteins were transferred
onto nitrocellulose (Hybond-C Extra, Amersham Biosciences), and the blot was probed
with guinea pig anti-ATS antibody (1:500) [a gift from Denise Mattei] for PfEMP1
detection.

Blots were incubated with alkaline phosphatase-conjugated guinea pig

secondary antibody (Pierce, 1:4000) and developed with BCIP/NBT solution (Sigma).

Immunoflourescence Assay (IFA)
Parasites were synchronized as stated above and immunofluorescence assays
were done as previously described (20). Blood films were double-stained with Rabbit
anti-Pf332 mAb51-22 diluted 1:500 followed by FITC-conjugated Goat anti-rabbit
secondary and Mouse anti-KAHRP mAb89 diluted 1:800 followed by Alexaflour 594
conjugated goat anti-mouse secondary (anti-Pf332 and anti-KAHRP were kind gifts of
Denise Mattei).

Nuclei were stained with 0.2 mg/ml 4′, 6-diamidino-2-phenylindole

(DAPI; Molecular Probes). Parasites were visualized by a DeltaVision CORE
microscope (Applied Precision).

Scanning Electron Microscopy (SEM)
SEM was performed with trophozoite (24-28 hours) iRBCs purified by magnetic
columns (CS columns; Miltenyi Biotec) followed by fixation (1% paraformaldehyde and
0.2% glutaraldehyde in HEPES buffer) for 30 minutes on ice. Cells were washed 3x in
HEPES buffer and stored at 4° C. The cells were post-fixed with 1% osmium tetroxide
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followed by rinsing with water and dehydration in a graded ethanol series (10%, 35%,
70%, 100%; 5 minutes each). Cells were subjected to chemical drying (HMDS), coated
with gold and palladium in a sputter coater, and viewed in a JEOL JSM6490 Scanning
Electron Microscope at 6 kV.
The number of knobs on the surface of the iRBCs (20 per cell line) was counted
using ImageJ software (Rasband, W.S., ImageJ, U. S. National Institutes of Health,
Bethesda, Maryland, USA, http://imagej.nih.gov/ij/, 1997-2012).

To determine

statistical significance, a one-way ANOVA followed by Tukey’s multiple comparisons
test was performed using GraphPad Prism v. 6 (GraphPad Software, La Jolla California
USA).

2D- Differential Gel Electrophoresis (DIGE)
Parasite cultures were synchronized 2x and harvested in late trophozoite stage
followed by purification on a magnetic column and saponin lysis. Two-Dimensional
DIGE and Protein ID was performed by Applied Biomics, Inc (Hayward, CA). Briefly,
after phosphostaining, the spots of interest were picked up by an Ettan Spot Picker
(Amersham BioSciences) based on the in-gel analysis and spot picking design by
DeCyder software. The gel spots were washed a few times then digested in-gel with
modified porcine trypsin protease (Trypsin Gold, Promega). The digested tryptic
peptides were desalted by Zip-tip C18 (Millipore). Peptides were eluted from the Zip-tip
with 0.5 ul of matrix solution α-cyano-4-hydroxycinnamic acid (5 mg/ml in 50%
acetonitrile, 0.1% trifluoroacetic acid, 25 mM ammonium bicarbonate) and spotted on
the MALDI plate (model ABI 01-192-6-AB). MALDI-TOF MS and TOF/TOF tandem
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MS/MS were performed on an ABI 4700 mass spectrometer (Applied Biosystems,
Framingham, MA). Both the resulting peptide mass and the associated fragmentation
spectra were submitted to GPS Explorer workstation equipped with MASCOT search
engine (Matrix science) to search the database of National Center for Biotechnology
Information non-redundant (NCBInr). Searches were performed without constraining
protein molecular weight or isoelectric point, with variable carbamidomethylation of
cysteine and oxidation of methionine residues, and with one missed cleavage also
allowed in the search parameters. Candidates with either protein score C.I.% or Ion
C.I.% greater than 95 were considered significant.

Immunoelectron Microscopy (IEM)
P. falciparum-infected erythrocytes were fixed for 30 min on ice in a mixture of
1% paraformaldehyde–0.2% glutaraldehyde in HEPES buffered saline. Fixed
specimens were washed, dehydrated, and embedded in LR-White resin (Polysciences,
Warrington, PA). Ultrathin sections on nickel grids were blocked for 30 min in PBS
containing 5% nonfat milk and 0.01%Tween 20 (PBS-Milk-Tween), incubated overnight
at 4°C in PBS-Milk-Tween containing rabbit anti-Pf-EXP2 serum (1/50 dilution), and
then incubated at 37°C for 1 h in PBS-Milk-Tween containing goat anti-rabbit IgG
conjugated with gold particles (15 nm diameter, British BioCell International, UK) at 1/20
dilution. Sections were examined with a JEM-1230 electron microscope (JEOL, Japan)
after staining with 2 % uranyl acetate and lead citrate.
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Results

Development of piggyBac Cytoadherence Screen Using Operetta® High
Content Screening
P. falciparum piggyBac mutant lines were tested for cytoadherence to receptor
CD36 expressed in CHO745 cells using a scaled format and auto-visualization on the
Operetta® High Content Screening System (HCS). Most P. falciparum strains bind to
CD36 receptor including NF54 used in this study. CHOCD36 and CHO745 (the wild-type
CHO cell line from which CHOCD36 was generated) were tested for relative amounts of
CD36 expression on the surface of the cell using a commercial anti-CD36 antibody.
CHOCD36 expresses an increased amount as expected due to the stable transfection of
an expression plasmid containing the gene for CD36, as previously described (19) (Fig.
2.1A). Visualization of CHO745 and CHOCD36 cells with anti-CD36 staining showed no
expression of CD36 (or below detection) on the surface of the cytoplasm of CHO745 (not
shown) while CHOCD36 had surface expression of CD36, as expected (Fig. 2.1B).
In order to increase the throughput of screening for cytoadherence, we modified
previous approaches in order to utilize the Operetta® HCS, which allows for automation
of many aspects of the assay. CHO cell nuclei were stained with Hoechst and iRBCs
were stained with anti-glycophorin A and visualized at 20x (Fig. 2.1C). The nuclei of
CHO cells were detected (Fig. 2.1D) and the cytoplasm (Fig. 2.1E) of the CHO cells
was defined based on the nuclei using Harmony® Software preset algorithms.
Glycophorin A-stained iRBCs were counted as attached to CHO cells if they were at
least 50% within the borders of the CHO cell cytoplasm (Fig. 2.1F). In order to validate
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this method as quantitative, purified P. falciparum NF54 iRBCs were incubated with
CHOCD36 cells at 10-fold dilutions from 10^8 iRBCs/ml to 10^4 iRBCs/ml (Fig. 2.2).
There was a high positive correlation between parasitemia and ∆Fc (fold change in
cytoadherence; as described in methods) with an R2 of 0.9845 (Fig. 2.2A).
Furthermore, the standard deviation in the dilution range of 10-10,000 was minimal and
could determine differences in binding (Fig. 2.2B). This value was therefore selected for
subsequent screening.

P. falciparum piggyBac Mutant Cytoadherence Screen
Thirty-four randomly chosen P. falciparum piggyBac lines from a mutant library of
P. falciparum lines were tested for cytoadherence.

piggyBac insertions were first

identified by tail PCR for transposon insertion (5) and in some cases the insertion site
was confirmed by whole genome sequencing (WGS) or transposon-directed insertion
site sequencing (TraDIS) (Supp. Table; manuscript in preparation). P. falciparum NF54
wild type and mutant lines were equalized in parasitemia and life cycle stage before
being allowed to bind to CHO745 and CHOCD36. Background binding was accounted for
by subtracting the average number of iRBCs that bound to CHO745 cells from the
number of iRBCs binding to CHOCD36. To determine the rate at which the mutant line
bound compared to NF54, the number of iRBCs binding to CD36 was divided by the
number of NF54 iRBCs binding to CD36 and transformed in order to normalize and
compare cytoadherence across experiments (see Methods). During the course of the
experiments, wild-type NF54 was used as a control in all cytoadherence assays and
after transformation set to zero for individual experiments. Mutants were considered
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decreased or increased in cytoadherence if the mean binding to CHOCD36 varied
significantly from the mean binding of NF54 (fold change equal to zero) as tested by a
one-way ANOVA followed by Dunnett’s multiple comparisons test.
Many mutants (47%) did not show a significant difference in binding phenotype
from the wild type NF54 strain (Fig. 2.3, 2.4, and Table 2.1). Twelve of the 34 mutants
tested exhibited a decrease in binding while only 6 showed an increase in binding to
CD36 (Fig. 2.3). Mutants were categorized by the assigned gene ontology (GO) based
on the ORF which the transposon disrupted.

All GO categories were found in the

mutants exhibiting no difference in cytoadherence, while the GO categories protein
modification and nucleic acid metabolism were enriched in both the decreased and
increased mutant groups (Fig. 2.4). This implies that the effect on cytoadherence in
these mutants is an indirect regulatory one, perhaps controlling PfEMP1 expression or
export.

Antigenic Variation in piggyBac Mutants
The PfEMP1 surface protein is expressed by a multi-gene family of var genes
(46), with only one var gene expressed by an individual parasite at any given time (42).
The consequence of var gene switching in culture could result in a false change in
cytoadherence phenotype due to the change in expression of the var gene rather than a
genetic defect affecting cytoadherence. (42). To test whether the piggyBac insertion
had impacted PfEMP1 transcription, mutant lines and the NF54 control were checked
for var gene expression through qRT-PCR. NF54 and the majority of mutant cell lines
tested expressed var gene PF3D7_0421100, indicating there was no antigenic
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switching between the mutant and parent cell lines during maintenance of cultures
(Table 2.1).

Incidentally, this var gene contains the DBL domain that has been

previously implicated in adhesion to CD36 receptors (39). Notably, a small subset of
mutants (PF3D7_1143500, PF3D7_1133700, PF3D7_0416500) that were decreased in
cytoadherence did not express this var gene. Interestingly, one mutant has an insertion
in a RNA-binding domain-containing gene (PF3D7_1133700) and another in a gene
involved in chromatin condensation (PF3D7_1143500) which may affect var gene
expression and therefore cause a decrease in cytoadherence. The last mutant has a
transposon insertion in a gene (PF3D7_0416500) upstream of the var gene that was
expressed in the parent line, indicating that the transposon insertion could affect the
expression of downstream genes however, further work to determine if a var gene is in
fact being expressed needs to be determined

Absence of PfMKP1 Expression Increases Cytoadherence to CD36
One of the mutants (C9) that showed an increase in CD36 binding contains a
piggyBac transposon insertion in gene PF3D7_1305500 (PfMKP1) (Fig. 2.3).

To

establish whether the cytoadherence phenotype was directly due to insertion in the
PfMKP1 coding sequence, the C9 mutant was complemented with an episomal copy of
the gene PfMKP1 with its native 5’ UTR and a 3’ 3x HA tag followed by a HRP3 3’ UTR.
RT-PCR previously confirmed that the complemented line reintroduced expression of
PfMKP1 RNA (4), and PfMKP1 protein expression was confirmed in the wild-type strain
NF54 and the complemented mutant by western blot using a monoclonal custom
antibody (anti-PfMKP1), while the C9 mutant showed no expression (Fig. 2.5A). To
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confirm that the increase in cytoadherence was due to the loss of expression of
PfMKP1, the CHO cell-based cytoadherence assay was performed with the PfMKP1
complemented line.

The increase in cytoadherence in the C9 mutant at 0.31-fold

increase over the wild type was statistically significant in a one-way ANOVA, while
complementation of PfMKP1 fully restored the cytoadherence phenotype to wild-type
levels (Fig. 2.5B). To determine whether the increased binding to CD36 was due to an
increase in nonspecific binding, rather than being CD36 specific, a purified receptorbased adherence assay was conducted. This assay found that both wild type NF54 and
the C9 piggyBac mutant only adhere to CD36 and not to other receptor molecules such
as ICAM-1 and CSA (Fig. 2.5C). An increase in binding to CD36 by the C9 mutant line
was also found in this different assay system, but experimental variation in this system
made this not a statistically significant association, emphasizing the benefits of the HCS
assay developed above.

Analysis of Knob Structures and Exported Proteins in C9 Mutant
In order to elucidate the mechanism for increased cytoadherence, we looked at
expression and localization of proteins known to be involved in cytoadherence, including
PfEMP1, KAHRP, and Maurer’s cleft proteins. In both the wild-type and C9 mutant line,
PfEMP1 expression was similar as determined by western blot (Fig. 2.6A). In addition,
using methods by Spycher et al. (45), we looked at RBC surface-exposed PfEMP1 and
detected no significant increase in PfEMP1 on the surface of the C9 mutant iRBCs as
compared to WT (Fig. 2.6A). Also, both the Maurer’s cleft protein Pf332 and KAHRP
showed similar localization patterns in WT and C9 by IFA (Fig. 2.6B).
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While IFA (Fig. 2.6B) did not detect a significant change in the expression or
localization of these few known exported proteins, many more proteins are exported
than can be detected by blot or IFA. To assess gross changes in export protein
associated structures, we used scanning electron microscopy to look at the knobs on
the iRBC surface of the mutant, wild type, and complemented mutant. Twenty iRBCs
collected in late trophozoite stage were analyzed for the average number of knobs on
the surface of the iRBC. SEM of the iRBCs demonstrated an increase in knobs on the
surface of the C9 mutant compared to both wild-type and complemented mutant (Fig.
2.7A-E). P. falciparum NF54 had an average of 8 knobs per μm2, the complemented
mutant had an average of 10 knobs, and the C9 mutant had an average of 16 knobs.
PfMKP1 disruption therefore clearly has a significant impact on knob formation

Global Analysis of Protein Expression in C9 Mutant
In order to tease out the relationship between this MAPK phosphatase and an
increase in knobs, we compared overall protein expression (Fig. 2.8). Two-dimensional
differential gel electrophoresis (2D-DIGE) was conducted to compare the mutant, wildtype, and complemented mutant protein expression.

Spots were chosen based on

differential expression in the mutant. Specific proteins that were overexpressed in the
mutant

included

an

endoplasmic

reticulum-resident

calcium

binding

protein

(PF3D7_1108600) and two fragment proteins of merozoite surface protein 7 (MSP7;
PF3D7_1335100) (Fig. 2.8). In addition, exported protein 2 (EXP2; PF3D7_1471100)
was found to be differentially expressed in two separate 2D-DIGE experiments (Fig.
2.8).
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Exported Protein 2 in C9 Mutant
Further experiments were carried out to determine the nature of EXP2 in the C9
mutant. A western blot of the complemented mutant, mutant, and wild type during ring
stages and trophozoites stages indicated no change in overall expression of EXP2 and
its oligomer forms (Fig. 2.9A) as first described by Bullen et al. (9). Furthermore, under
immunoelectron microscopy, gold staining of EXP2 indicated no aberrant change in
localization patterns as EXP2 was found in the PVM in both the wild-type and mutant
(Fig. 2.9B).

Further attempts to pull-down EXP2 and look for post-translational

modification changes that may contribute to the differential expression were
unsuccessful.

Discussion
Cytoadherence plays a critical role in malaria pathogenesis, and has been one of
the most studied aspects of P. falciparum biology. However, the assays to measure
cytoadherence such as purified receptor or flow-based assays have often been
qualitative in nature and involve labor-intensive methods that cannot be scaled. During
the course of this work we have developed a novel scalable method for P. falciparum
cytoadherence using High Content Screening that has a wide range of applications.
Recently, a similar study gave proof of principle to the HCS method for use in drug
screening of compounds that explicitly inhibit cytoadherence to cells expressing CSA
(receptor involved in placental malaria) (27).
Using this assay in conjunction with a library of P. falciparum piggyBac mutant
lines, we identified several genes potentially involved in cytoadherence that have not
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been previously described, most of which are annotated as hypothetical proteins.
Several of the genes with cytoadherence phenotypes are involved in nucleic acid
metabolism and protein modification, suggesting that they have a regulatory affect.
Some of these mutants may directly affect transcription of exported proteins, such as
PF3D7_0404100 and PF3D7_1136000 which contain insertions in putative AP2
transcription factor genes and both exhibit a decrease in binding to CD36 compared to
wild type. In addition, PF3D7_0611800, which had an increase in cytoadherence, has
an insertion in a gene that is not annotated as an AP2, but is an orthologue to genes
that are annotated as hypothetical AP2s in other Plasmodium species. At this time, the
targets of these transcriptional regulators are not known but PF3D7_0404100 has been
implicated in sexual development of the parasite (32). At least one AP2 factor PfSIP2
has been found to be involved in the silencing of var genes through its involvement in
heterochromatin formation (16) and ApiAP2 binding sites have been identified upstream
of var genes (10) signifying that AP2s may be involved in regulation of genes involved in
cytoadherence.
We also found that insertional mutations in genes with putative phosphatase and
kinase activity affect the relative cytoadherence of the iRBC.

One piggyBac mutant

with an insertion in a P. falciparum-specific kinase, FIKK 9.3 (PF3D7_0902200), was
found to have decreased cytoadherence properties while two mutants with insertions in
putative phosphatase genes, PF3D7_0615900 and PF3D7_1305500, demonstrated an
increase in cytoadherence suggesting a role for phosphorylation of proteins in
cytoadherence. FIKK is a multi-gene family that encodes exported kinases only found
in Plasmodium sp. FIKKs have been implicated in RBC rearrangement and stabilization
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(8, 34) which further indicates a role for phosphorylation in stabilization of P. falciparum
proteins within the RBC cytosol as a mechanism for cytoadherence.
We chose to further study in detail the piggyBac mutant which had an insertion in
an atypical MAPK phosphatase gene (PfMKP1). The loss of expression of PfMKP1 in
the piggyBac mutant C9 increased cytoadherence and the number of knobs on the
surface of iRBCs, although it did not directly impact the expression of KAHRP, a major
structural component of knobs (data not shown). KAHRP does not directly interact with
receptors such as CD36, but knob formation is important for PfEMP1 surface
presentation and can indirectly affect cytoadherence (25, 35, 40, 51). We believe the
fold-change increase in cytoadherence in the piggyBac mutant C9 is due to the increase
in knobs on the iRBC and therefore an increase in adhesive nature. That this was a
direct effect of PfMKP1 disruption was genetically validated by complementation of the
mutant line with the native PfMKP1 gene.
Furthermore, in the 2D-DIGE analysis, an ER-resident protein and exported
proteins (EXP2 and MSP7) were found to be differentially regulated in the mutant. The
ER-resident protein (PfERC; PF3D7_1108600) has been implicated in the classical
protein export pathway in P. falciparum (2, 28) and its increase in expression may
designate a role for PfMKP1 early in the export pathway. In addition, both EXP2 and
MSP7 were found to be in higher quantities in the C9 mutant. Both these proteins are
known to be exported to the PVM or RBC. In this work, two separate DIGE experiments
were carried out and both showed a difference in expression in EXP2 in the mutant as
compared to wild-type and complemented mutant.

However, in the second DIGE

experiment performed the change was not as significant. In addition, follow up studies
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on EXP2, IEM and western blot analysis, indicated no discernable change in EXP2.
Together, this information indicates a change in the protein export pathway due to the
loss of expression of PfMKP1.

However, the exact mechanism for the increase of

knobs due to the loss of PfMKP1, an atypical MAPK phosphatase, remains unclear.
The putative substrate of PfMKP1 is a mitogen-activated protein kinase (MAPK)
of which there is two identified in the P. falciparum genome, Pfmap1 and Pfmap2 (13,
17, 30).

MAPK pathways are complex intracellular signaling systems which use a

phosphorylation cascade to allow a cell to respond to the external environment.
Although homologues of the kinases in the classical three-component system of the
MAPK pathway are not present in P. falciparum, other putative kinases that can fulfill
the role of the three-component system have been identified (3, 31). Pfmap2 is an
atypical MAPK and has been found to be necessary for P. falciparum intra-erythrocytic
development and male gametogenesis (14, 38, 47), while a role for Pfmap1 has not
been identified.

The involvement of the MAPK pathway in Plasmodium cytoadherence

has yet to be studied but MAPK pathways in other organisms can lead to cell
cytoskeleton changes and alterations in the adhesive state of the cell (18, 44).
Post-translational modification of proteins, specifically phosphorylation, can lead
to changes in localization of proteins and protein-protein interactions.

Invasion of the

RBC by P. falciparum merozoites is dependent on a protein complex that allows the
parasite to actively invaginate the RBC (6, 24). This complex forms through proteinprotein interactions that are dependent on phosphorylation (23).

Furthermore, the

interaction between KAHRP and PfEMP1 at the RBC membrane was also found to be
dependent on phosphorylation due to the action of Casein Kinase II (22). Knobless
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parasites were found to exhibit a different phosphorylation pattern of proteins compared
to parasites that form knobs in iRBCs, leading to the potential of the parasite-produced
proteins to not only affect phosphorylation within the parasite proteome, but within the
host, also.

Within the host cell, cytoadherence of iRBCs causes changes in

phosphorylation and CD36 receptor recruitment to the cell surface which further
increases the strength of the binding interaction (12, 21, 52). Other parasite proteins
that are exported or involved in the machinery of exportation have identified
phosphorylation sites (29, 37, 49) but the function of these sites has yet to be studied.
Herein, we have described a method that can be used to identify target genes
and putative pathways for drug discovery in severe malaria. The events leading up to
cytoadherence of an iRBC within a host are complex and still mostly unknown. During
this study, we developed a novel approach for discovering new genes that may directly
or indirectly affect cytoadherence.

We further identified the MAPK pathway in P.

falciparum as a putative pathway that can affect protein export in P. falciparum. Further
work to determine the relationship between this pathway and cytoadherence could lead
to the further elucidation of the importance of the MAPK signaling pathway in P.
falciparum.

Because cytoadherence is an important phenomenon that causes

pathogenesis in the host, drugs that alter this pathway may be used to treat severe
malaria and reduce deaths due to cerebral malaria.
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Table 2.1: Description of P. falciparum piggyBac Mutants Used in Cytoadherence Assay.

PlasmoDB ID (plasmodb.org/plasmo/; v. 11.0)
ND = Not determined
WGS = Whole genome sequencing
TraDIS = Transposon-directed insertion site sequencing
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Figure 2.1: Development of Cytoadherence Assay Using Chinese Hamster Ovary
Cells and Operetta® High Content Screening. Chinese Hamster Ovary (CHO) cells
were tested for expression of the receptor CD36 by western blot (A), and by
immunofluorescence (B) imaged by Operetta at 20x objective, Blue = Hoechst 33342
staining of nuclei, pink = anti-CD36 staining, and the arrow indicates bound iRBCs.
CHO cells and iRBCs were stained with Hoechst 33342 (blue=CHO nuclei) and antiGPA (pink=iRBC) and imaged on the Operetta at 20x (C). Harmony® software
algorithms determined CHO cell nuclei (D) and CHO cytoplasm (E), and Harmony®
software counted iRBCs (pink dots) within the boundaries of the CHO cells (multicolored outline) (F).
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Figure 2.2: Validation of Cytoadherence Assay using Operetta® HCS and ∆Fc
Formula. (A) Linear regression of NF54 binding across a series of dilutions gave a high
R-squared value. (B) Bar chart of data obtained in 2 different experiments using
dilutions of NF54 demonstrated increased standard deviations at both the high and low
end of dilution spectrum.
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Figure 2.3: Cytoadherence Screen of piggyBac Mutants. P. falciparum clone NF54 and mutants (GeneDB IDs indicate
locus of transposon insertion) are shown on a graph according to the ∆Fc which is defined as the fold change in binding to
CHO-CD36 cells compared to NF54 parent line. Gray bars indicate mutants significantly increased in binding (n=6), white
bars are not significantly different than wild-type NF54 (n=16), and black bars indicate mutants significantly decreased in
binding
(n=12).
Statistical
significance
was
determined
by
one-way
ANOVA
at
p<0.05.
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Figure 2.4: Categorization of piggyBac Mutants Tested in Cytoadherence Screen.
(A) piggyBac mutant lines were characterized as increased (n=6), decreased (n=12), or
no change (n=16) compared to NF54 wild-type. (B) Gene ontology categorization of
mutants that were decreased, exhibited no change, and increased in cytoadherence as
compared to wild-type NF54. Gene ontologies were based on the gene containing the
piggyBac insertion as described in PlasmoDB product description or by protein domain
homology to other genes.
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Figure 2.5: Insertional Mutant of PfMKP1 (C9) Demonstrates Increased Binding to
CD36 Receptors and is Restored to Wild-type Binding When Complemented. (A)
Western blot of parasite lysate showing expression of PfMKP1 in wild-type and
complemented mutant but not in mutant C9 strain, (B) Fold change in cytoadherence of
C9 mutant and C9 complemented mutant compared to NF54 wild-type, * indicates
statistical significance at p<0.05. (C) NF54 (WT) and insertional mutant (C9) were
tested against purified receptors Cluster of Differentiation 36 (CD36), Intercellular
adhesion molecule 1 (ICAM-1), and Chondroitin sulfate A (CSA).
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Figure 2.6: Comparison of Proteins Involved in Cytoadherence between NF54
Wild-type and C9 piggyBac Mutant. (A) Protein expression of PfEMP1 using anti-ATS
sera. Top panel shows only surface exposed protein and bottom panel is total PfEMP1
in cell. (B) Immunofluorescence of proteins involved in cytoadherence in C9 and NF54
cell lines shows no aberrant changes in localization of common proteins in export
pathway. Maurer’s cleft protein marker (Pf332) and knob-associated histidine rich
protein (KAHRP) were stained with antibodies and DAPI was used for nuclei
visualization.
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Figure 2.7: Scanning Electron Microscopy Shows Increased Knobs on Surface of
C9 Parasite Line. (A) uninfected RBC, (B) NF54 iRBC, (C) C9 iRBC, (D) C9_comp
iRBC. (E) Statistical analysis of knobs per micron squared using a one-way ANOVA
followed by Tukey multiple comparison test, n=20, demonstrated significant difference in
C9 mutant compared to NF54 and C9 complement.
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Figure 2.8: Changes in Proteome of C9 Mutant.
Two-dimensional gel
electrophoresis of piggyBac mutant C9 (blue), wild type NF54 (green), and
complemented mutant (red). White spots indicate overlapping expression between all 3
strains. Enlarged areas show increased expression in C9 mutant of ER-resident
calcium binding protein (ERD), exported protein 2 (EXP2), and fragments of MSP7. (B)
Fold increase in expression of C9 mutant over wild-type and C9 complemented mutant.
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Figure 2.9: Evaluation of Exported Protein 2 (EXP2) in NF54, C9 Mutant, and
Complemented Mutant Cell Lines. There was no difference observed in overall
expression of EXP2 by (A) Western blot analysis or localization by (B) immunoelectron
microscopy, arrow indicates gold particle staining of EXP2 in the parasitophorous
vacuole membrane (PVM).
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CHAPTER THREE:
CHARACTERIZATION OF AN ATYPICAL TYPE II MITOGEN ACTIVATED PROTEIN
KINASE PHOSPHATASE IN PLASMODIUM FALCIPARUM

Introduction
Plasmodium falciparum is an intracellular parasitic protozoan which causes
pathogenesis by invading erythrocytes within the human host.

Signaling pathways

involving phosphorylation have been studied in this parasite and found to be important
for invasion, protein export and host cell remodeling (10, 11, 23, 31). P. falciparum has
~99 putative protein kinase or protein kinase-like coding genes in its genome (1, 32)
and 27 protein phosphatase coding genes (34) as well as a minimum of 650 proteins
with identified phosphorylation sites (26). Based on genomic bioinformatic analysis, the
P. falciparum kinome is similar to most eukaryotic cells but has an additional family of
kinases not found in other genera (FIKK) and is missing homologues to tyrosine and
STE (Sterile yeast) kinases (26, 32). Although tyrosine kinases have not been identified
in the genome, phosphoproteomic analysis of P. falciparum has revealed tyrosine
phosphorylation of parasite proteins at rates similar to other eukaryotic cells (<1% of all
phosphorylation sites) (26). Because of the lack of STE kinase homologues in the
genome, there are no apparent homologues to mitogen activated protein kinase kinases
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(MAPKK) or mitogen-activated protein kinase kinase kinase (MAPKKK) and therefore it
is unknown if the MAPK pathway functions in P. falciparum.
The MAPK pathway is found in eukaryotic cells and allows a cell to sense its
external environment and respond to stimuli. The MAPK pathway is responsible for
many cellular changes within the cell such as proliferation, differentiation, growth, and
adhesion (27).

The MAPK pathway utilizes a phosphorylation cascade to transmit

external stimuli through a cell to affect transcription and expression of proteins within
the cell (3). In this pathway, there is a tiered level of kinases where a membrane-bound
tyrosine kinase receptor (ex. Insulin receptor or EGRF) recognizes the initial external
signal and transmits it across the cell membrane to a MAPKKK, which phosphorylates a
MAPKK, and in turn phosphorylates a MAPK. MAPKs are phosphorylated within their
active pocket on the conserved motif TXY where both the Thr and the Tyr need to be
phosphorylated in order to activate the kinase. If a MAPK auto-phosphorylates the Tyr
without the activation of the MAPKK, off-target substrates may be phosphorylated.
When a MAPK is activated, it shuttles into the nucleus where it interacts with
transcription factors to change transcription within a cell. A MAPK can be deactivated
through dephosphorylation of the TXY motif dependent on a MAPK phosphatase (MKP)
in either the cytoplasm or nucleus of a cell.
Within P. falciparum two MAPK homologues have been identified, Pfmap1 and
Pfmap2 (6-8, 25, 33). Pfmap2 is thought to be required for growth of P. falciparum
within the red blood cell due to its inability to be knocked out (7).

In P. berghei,

Pbmap2, the orthologue to Pfmap2, is not necessary for growth in the intra-erythrocytic
stage but plays a role in male gametogenesis (14, 25, 29). Pfmap2 does not have the
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canonical TXY motif but instead a TSH motif in which phosphorylation of the Thr is
critical for enzyme activation in vitro (8, 21). The other identified MAPK in P. falciparum,
Pfmap1 is not necessary for intra-erythrocytic growth of the parasite and has yet to be
assigned a function (6, 7, 18). This kinase does have the conserved TXY motif which
its phosphorylation is critical for catalytic activity in vitro (12). To date, there have been
no identified MAPKK, MAPKKK, or tyrosine kinase receptors in P. falciparum. However,
kinases such as Pfnek-3 and Pfnek-1 are capable of phosphorylating MAPKs on their
active site in vitro and may act as MAPKKs in vivo (9, 19-22). There are 2 putative
MAPK phosphatase (MKP) homologues in the P. falciparum genome (34), but their role
in the MAPK pathway has yet to be demonstrated. Both of these have sequences
indicative of type I MKPs where there is a single dual-specificity phosphatase (DUSP)
domain. One of these MKPs, PfYVH1 has significant homology to the human YVH1 and
can translocate between the nucleus and cytoplasm of the parasite (16), a feature found
in MKPs (17).
Recently, we have published on an atypical-MKP in the P. falciparum genome,
PfMKP1 (2). This MKP has a sequence structure indicative of a type II MKP with an
inactive-rhodanese (RHD) domain followed by a DUSP domain. It is atypical in that the
conserved CX5R motif found in all catalytically active DUSP domains is replaced by a
CX14I motif. Previously, we found PfMKP1 to play a role in intra-erythrocytic growth of
the parasite (2). Here, we further characterize PfMKP1 by establishing its catalytic
activity and identify its potential substrate as Pfmap1, further demonstrating evidence
for the presence of a functioning MAPK pathway in P. falciparum.
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Materials and Methods

Recombinant Protein Constructs
PfMKP1 (PF3D7_ 1305500) sequence was retrieved from PlasmoDB.

A

truncated version (aa1-560) where the putative transmembrane domains were removed
was used for production of a synthetic codon-optimized construct for expression in E.
coli with an N-terminal glutathione-S transferase (GST) tag (GeneArt). The truncated
gene construct was subcloned into pGex-2T and transformed into E. coli DH5α (NEB)
and E. coli BL21 (NEB) for mutagenesis and expression, respectively. Single domain
GST-tagged constructs, rhodanese (RHD; aa1-189) and dual-specificity phosphatase
(DUSP; aa210-560), were also made and transformed into BL21 for expression (see
Fig. 3.1 and Table 3.1). GST only was produced from pGEX-2T as a control. In some
cases, to improve expression, constructs were subcloned into pCOLDIV (TaKaRa) and
transformed into BL21 (see Table 3.1).
Pfamp1 (kinase domain only)-NusA-His6 and Pfmap2-NusA-His6 constructs in
pCOLDIV vector were supplied as a kind gift from Isabelle Lucet (Monash University).
Both plasmids were transformed into BL21 cells for expression of protein. Additionally,
a construct of NusA-His6 only was made by using primers (see Table 3.1) to amplify the
plasmid minus the Pfmap2 gene. The plasmid was ligated and transformed into BL21
for expression.
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Expression of Recombinant Proteins
For protein expression, 3 ml of overnight culture (in LB plus 100 μg/ml ampicillin)
was inoculated into 1 liter (LB with 100 μg/ml ampicillin). The culture was grown to log
phase (OD600, ∼0.4 to 0.6), and protein expression was induced by the addition of 1
mM IPTG (isopropyl-β-D-thiogalactopyranoside).

E. coli BL21 cells containing the

pCOLDIV expression vector for protein expression were incubated at 15°C with shaking
for 20-24 hours. E. coli BL21 with pGEX-2T plasmid for expression of proteins were
incubated at room temperature (~27° C) overnight with agitation. Bacterial cells were
collected by centrifugation at 5,000 × g for 15 min, suspended in 25 ml lysis buffer
(PBS, 0.5% Triton X 100, 10 mM DTT, 1 mg/ml lysozyme, 1:1000 protein inhibitor
cocktail),incubated on ice for 30 min followed by sonication. The resulting lysate was
cleared of debris by centrifugation at 18,000 × g for 30 min at 4°C. Supernatant was
stored at -20° C until purification.

Purification of Recombinant Proteins
Supernatant containing soluble expressed protein was diluted with 1x PBS and
loaded onto either glutathione agarose (Molecular Probes) or Dynabeads His-tag
Isolation and Pulldown magnetic beads (Invitrogen). The lysate was allowed to mix with
the beads overnight at 4° C with rotation in order to facilitate binding. The glutathione
sepharose was spun at 1000xg for 1 minute and washed with 10 volumes of PBS 5x.
Purified proteins were either used for pull-down interactions with beads or eluted off the
beads with 5mM reduced glutathione in Tris-HCL buffer, pH 8.

Dynabeads were

collected using a magnet and washed 5x with phosphate buffer (100 mM Na-
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Phosphate, pH 8, 600 mM NaCl, 0.02% Tween 20). Purified proteins were either used
for pull down interactions on beads or eluted off the beads with elution buffer
(phosphate buffer, 300 mM imidazole). The eluted proteins were concentrated and the
buffer was exchanged for PBS in a centrifugal filter device (Millipore) with a 10 kDa
cutoff.

Mutagenesis of PfMKP1 Dual-Specificity Phosphatase (DUSP) Domain
The DUSP domain construct was used for site-directed mutagenesis (SDM).
Vector pGex-2T with the DUSP domain was used as a template for SDM.

Two

mutagenesis reactions were performed, C388A and I398R (see Table 3.1 for primer
sequence), using overlapping PCR of the plasmid.

Plasmids were ligated and

transformed into DH5-alpha for propagation and sequence confirmation.

After

sequences were confirmed, plasmids were prepared from the correct clones and
transformed into BL21 cells for expression. Expression and purification of proteins was
conducted as stated above.

p-Nitrophenyl

Phosphate

and

Fluorescein

Diphosphate

Protein

Phosphatase Assays
Purified proteins were incubated with p-Nitrophenyl phosphate (pNPP) (Anaspec)
or fluorescein diphosphate (FDP) (Anaspec) for 1 hour at 37° C in a 96-well plate. The
OD405 was measured for pNPP wells and the Excitation/Emission (485/528 nm) was
measured for wells containing FDP substrate using a Spectramax M2 (Molecular
Devices) plate reader and Softmax Pro (v. 5.4.5). Samples to which no enzyme was
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added were used as negative (-) controls. Alkaline phosphatase was incubated with
substrate as above for a positive (+) control. Purified GST protein with substrate was
used as a normalizer of background. All results were subtracted by GST readings in the
figure. Results are given as the average of 2 wells. The experiment was repeated
twice with a representative assay reported.

Recombinant Protein Pull-Down Assay
Recombinant PfMKP1 proteins and Pfmaps were expressed in E. coli as above.
The pull-down was performed as described in manufacturer’s protocol (Invitrogen).
Briefly, purified PfMKP1 proteins (DUSP, RHD, RHD+DUSP) were incubated with
Pfmap1, Pfmap2, or NusA only bound to Dynabeads for 2 hours at 4° C with continuous
mixing. Beads were washed 10x with pull-down buffer (6.5 mM Na-Phosphate, pH 7.4,
140 mM NaCl, 0.02% Tween-20). Bead and protein mixture were resuspended in 4x
reducing SDS buffer and subjected to SDS-PAGE followed by western blot with antiGST (Sigma).

Parasite Lysate Pull-Down Assay
Recombinant full-length PfMKP1 (RHD + DUSP domain) and GST only were
expressed in BL21 and purified using glutathione agarose overnight at 4° C as
described above.

Mixed stage P. falciparum NF54 iRBCs were collected by

centrifugation and saponin lysed followed by extensive washing in PBS to remove RBC
proteins. Free parasites were resuspended in lysis buffer (1% TX100, 50 mM Tris–Cl
pH 8.0, 5 mM EDTA with complete protease inhibitor cocktail (Sigma) and phosphatase
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inhibitor) and lysed on ice for 30 minutes. Samples were subjected to centrifugation
(14,000xg) for 15 minutes to remove insoluble proteins.

The soluble portion

(supernatant) was used for the pull-down assay. Agarose with bound PfMKP1 of GST
were mixed with P. falciparum NF54 cell lysate and incubated with constant rotation for
1 hour at 4° C. The beads were spun at 1000xg for 1 minute and washed 10x with PBS
+ Tween-20. The beads were then resuspended in reducing SDS buffer and run on a 412% gradient gel Tris-glycine gel.

Mass Spectrometry Identification of Parasite Proteins from Pull-Down
Assay
After SDS-PAGE, the gel was stained with Coomassie blue followed by
destaining. Protein bands were seen throughout the lane. Each lane was cut into 10
sections and further processed for analyzing by LC-MS/MS.

The gel pieces were

processed to remove all SDS, reduction and alkylation of the proteins and then in-gel
digestion using trypsin (Promega). The digested proteins were resuspended in 0.1%
formic acid and run on a 60-minute gradient for MS/MS on a linear ion trap nLC/MS
(LTQ XL, Thermo) equipped with XCalibur (version 2.0.7) data acquisition software.
The resulting identified peptides were run against a merged Homo sapiens - P.
falciparum database from UniProt (http://www.uniprot.org/) using Mascot (Matrix
Science, London, UK; version 2.2).

The identified proteins were analyzed using

Scaffold (version Scaffold_3_00_08, Proteome Software Inc., Portland, OR) to validate
MS/MS based peptide and protein identifications. Peptides were accepted if the
probability was > 95.0% as specified by the Peptide Prophet algorithm and protein

76

identifications were accepted at probabilities > 95% as specified by the Protein Prophet
algorithm. To determine significant enrichment of proteins a Fisher’s exact test was
used and the p-value is given in the figure.

Parasite Culture
P. falciparum NF54 wild-type, C9 mutant parasite, and complemented mutant
were used for this study. The piggyBac mutant parasite line C9 and the complemented
piggyBac mutant (C9 complement) were previously described (2). All cultures were
maintained using standard techniques. Plasmodium falciparum wild-type NF54 and the
mutant clones were cultured according to standard methods at 37°C and gassing (5%
O2 and 5% CO2, nitrogen balanced) with 5% hematocrit (O+ blood, Interstate Blood
Bank) in RPMI 1640 medium (Invitrogen) supplemented with 0.5% Albumax II
(Invitrogen), 0.25% sodium bicarbonate and 0.01 mg/ml gentamicin. The complemented
piggyBac mutant was maintained with 2 μg/ml Blastocidin-D to maintain the episome.
Parasite lines were kept in culture for no longer than 3 months as to keep the integrity of
the transposon insertion and minimize antigenic variation.

For assays, parasite lines

were synchronized during ring stage a minimum of 2x using 5% sorbitol unless
otherwise stated.

P. falciparum Protein Extraction and Western Blot
Parasite culture was synchronized twice with 5% sorbitol and parasites were
harvested 5 hours later for ring stage and 28 hours later for trophozoites stage. All
parasites were harvested by incubating with PBS with 0.1% saponin in order to lyse
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RBCs. Cells were washed 3x to remove RBC debris and the resulting parasite pellet
was suspended in SDS-PAGE buffer.

For ring stage parasites, parasitemia was

equalized to 5% between cultures. For trophozoites stages, culture was harvested and
iRBCs were purified through MACS magnetic column (Miltenyi Biotec). The purified
iRBCs were counted by hemocytometer and adjusted to 1 x 10^7 cells/ml to standardize
the number of iRBC across strains.

Samples were loaded onto a gradient SDS-PAGE

gel and western blot was conducted in the same manner as stated above using Mouse
anti-PyBiP (a gift from Sebastian Mikolajczak, unpublished) at 1:1000 and Rabbit antiPfmap1 (a gift from Christian Doerig) at 1:1000 or Rabbit anti-Phospho-p44/42 MAPK
(Erk1/2) (Cell Signaling; proprietary synthetic phosphopeptide corresponding to
residues surrounding Thr202/Tyr204 of human p44 MAP kinase) at 1:2000. Secondary
HRP conjugated goat anti-rabbit or anti-mouse (Jackson Laboratories) was used at a
1:10,000 dilution.

Densitometry on the resulting bands was conducted using a

PharosFX Plus imager (Biorad) and Quantity One software.

Pfmap1 Localization within the Parasite
Late stage parasites after synchronization were purified using MACS magnetic
column (Miltenyi Biotec).

The iRBCs were fixed in solution and processed for

immunofluorescence using methods previously described (30).

Rabbit anti-Pfmap1

(1:500) was used for the primary and Anti-Rabbit Alexa Fluor® 594 (Life Technologies)
was used for the secondary. Hoechst 33342 (10 μg/ml) was used to stain the nuclei.
Parasites were visualized by a DeltaVision CORE microscope (Applied Precision).
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Results

Recombinant PfMKP1 Shows In vitro Phosphatase Activity
Bioinformatic analysis of PfMKP1 predicted it is an inactive phosphatase or has
significantly reduced activity due to mutations in the active motif CX5R (2). To determine
if PfMKP1 possesses phosphatase activity, we expressed and purified single domain
and dual domain PfMKP1 as GST fusion proteins from E. coli for a generic substrate
phosphatase assay (Fig. 3.1B). We used PfYVH1, a known DUSP in P. falciparum (17),
as a positive control for the assay.

The DUSP domain and the full-length protein

demonstrated similar activity to a positive control while the RHD domain alone showed
no enzymatic activity (Fig. 3.2A). To further demonstrate if the altered CX5R motif was
involved in decreasing enzymatic activity, the DUSP domain was mutated in suspected
residues of catalytic activation (Fig. 3.1C). Unexpectedly, the mutation of C383A in the
DUSP domain increased activity of the enzyme while the mutation I399R decreased
activity to background level (Fig. 3.2A). The assay was repeated in a generic peptide
substrate assay and again the mutated DUSP C383A demonstrated increased activity
compared to the wild-type DUSP and full-length domain (Fig. 3.2B). The data shown
are representative of data obtained from independent purifications.

In vitro Binding of PfMKP1 to Pfmaps
Single domain and dual-domain recombinant PfMKP1 proteins were used to test
in vitro interaction with Pfmap1 and Pfmap2. The dual-specificity (DUSP) domain was
able to bind both Pfmap1 and Pfmap2 but not the NusA only control (Fig. 3.3A). Both
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the single rhodanese (RHD) domain and the dual-domain proteins (RHD+DUSP) bound
only to Pfmap1 and not to either Pfmap2 or NusA (Fig. 3.3A). Furthermore, interaction
of the recombinant full-length PfMKP1 protein was tested against parasite lysate to see
if native Pfmaps bind to PfMKP1. Both the full-length PfMKP1 and GST only (control)
were produced and bound to glutathione agarose.

P. falciparum NF54 lysate was

incubated with both samples. The beads were washed and run on a SDS-PAGE gel.
The entire lane of the gel was cut out and divided into 10 samples for LC-MS/MS
analysis. Five proteins were enriched in the PfMKP1 sample as compared to the GST
only (Fig. 3.3B) including Pfmap1 (p = 0.011). Pfmap2 was not found in the protein
identification.

Pfmap1 in vivo Expression and Phosphorylation
Pfmap1 expression was determined in both the early ring stages and the late
trophozoite stages of the parasite life cycle in NF54 wild type, C9 mutant, and C9
complemented parasite lines. Pfmap1 was found to be expressed throughout all stages
of the life cycle (Fig. 3.4A, top panel) which is similar to previous work (12). We used a
commercial antibody that recognizes the pTpY motif of MAPK ERK1/2. This antibody
was predicted to recognize phosphorylated Pfmap1 TDY motif based on sequence
homology. We found that the active site of Pfmap1 TDY is phosphorylated in late
trophozoite stage but not in ring stage (Fig. 3.4A, middle panel). In the C9 mutant, the
phosphorylated motif was increased as compared to the wild type and the complement.
Based on densitometry of the bands, the proportion of phosphorylated to total Pfmap1
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was higher in the mutant (52%) compared to less than 10% for the wild-type and
complement (Fig. 3.4B).

Pfmap1 Localization in Late Stage Parasites
Localization of Pfmap1 was determined by immunofluorescence assay (Fig. 3.5)
in the late stages of the cell cycle where PfMKP1 would be highly expressed and the
phosphorylated form of Pfmap1 is more highly expressed. Pfmap1 was found diffused
through the cytoplasm in both the wild-type and complemented C9 mutant. In contrast,
in the C9 mutant, Pfmap1 appeared more in a nuclear, punctate pattern rather than
diffused through the cytoplasm (Fig. 3.5). This localization pattern was seen in at least
5 parasites per parasite line used.

Discussion
PfMKP1 was previously described as an atypical MAPK phosphatase which
affected erythrocytic growth of P. falciparum by lengthening the cell cycle in the pre-S
phase (2). Here we have further described the characteristics of this protein. We found
that PfMKP1 dual-specificity domain does confer phosphatase activity to the protein in a
generic substrate phosphatase assay. Interestingly, we found that mutating the Cys in
the predicted CX5R motif to an Ala increased phosphatase activity in the generic
substrate assay. This unusual result was repeated with a separate assay and found to
be similar. This could indicate that the canonical CX5R (or the atypical CX14I seen in
PfMKP1) motif is not responsible for catalytic activity of the enzyme and therefore other
residues should be explored. Specifically, there are 2 Lys residues found within the
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CX14I motif that in a homology model forms a loop structure around the putative active
site and may be involved in the enzymatic activity of the protein (4).

In addition, the

aspartic acid which is present in the active site pocket of PfMKP1 could act as acidbase catalysis to remove a phosphate group taking the place of the catalytically
important cysteine.
PfMKP1 is a type II MKP which possesses 2 domains, an inactive rhodanese
(RHD) and an active dual-specificity phosphatase domain (DUSP). We further wanted
to explore if PfMKP1 uses one of the two MAPKs found in the P. falciparum genome,
Pfmap1 or Pfmap2, as a substrate. We found that the DUSP domain binds to either
Pfmap1 or 2 in an in vitro pull-down assay in vitro but that the full-length protein (RHD +
DUSP domain) and the single RHD domain would only interact with Pfmap1.
Furthermore, a pull-down using recombinant full-length PfMKP1 was able to enrich for
native Pfmap1 from parasite whole cell lysate.

In type II MKPs, the inactive rhodanese

domain confers substrate specificity and acts as a MAPK binding domain (MKB) (15). A
kinase interaction motif (KIM) is typically found within MKB domains and allows for
binding specificity with its MAPK partner (24).

MAPKs contain a common docking

domain with a conserved DXXD motif found on the opposite side of the active pocket on
the MAPK which enable specificity of its interaction with both MAPKKs and MKPs (28).
We hypothesize that a stretch of amino acids in the RHD domain (aa167-182:
IYNKKMMIQINKEM) act as a KIM (Appendix B) that potentially interacts with a common
docking domain in Pfamp1 (aa316-319: SIID) (Appendix B).
The expression of PfMKP1 affected the phosphorylation and localization of
Pfmap1. We found that the expression of Pfmap1 in the mutant was unchanged (or
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slightly lower, possibly due to feedback mechanisms but not confirmed) compared to
wild-type and complemented mutant (Fig. 3.4). However, the phosphorylation status of
Pfmap1 in the mutant was increased as compared to the wild-type and complemented
mutant (Fig. 3.4). Furthermore, Pfmap1 in the mutant parasite line is localized in the
nuclear region compared to diffused throughout the cytosol in the wild-type and
complemented mutant (as seen in previous studies (7)). Recently, P. berghei map1
was found to be localized to the nucleolus of the parasite in liver stages enabled by its
conserved nuclear localization sequence (NLS) found in all map1 orthologues in
Plasmodium (33).
Localization of Pfmap1 using rabbit polyclonal anti-Pfmap1 did give background
in the immunofluorescence. In order to fully demonstrate that translocation of Pfmap1 is
occurring, differential protein preparations could be used to assay for the kinase in
nuclear versus cytosolic preps as was performed in PfYVH1, another enzyme predicted
to be part of the MAPK pathway (17). In addition, more quantitative analyses of IFAs
using a cytosolic and nuclear protein marker and looking for co-localization of Pfmap1
with either marker could definitively prove the translocation of Pfmap1 during the
parasite life cycle and in response to phosphorylation of the TXY motif. Taken together,
both the increased phosphorylation and the change in localization patterns, indicates
that the Pfmap1 may stay activated in the mutant parasite line longer than in the wildtype. This over-activation of Pfmap1 may lead to the phenotypic changes we saw in the
mutant cell line, such as cell-cycle lengthening and increase in knob surface structures
((2); Chapter 2).
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Pfmap1 has demonstrated kinase activity in vitro that is dependent on the
phosphorylation of the TDY motif (12). However, when Pfmap1 was knocked out, there
was no apparent effect on erythrocytic growth of the parasite and the only phenotype
was an increase in Pfmap2 expression (7).

Other phenotypes within the Pfmap1

knockout have yet to be studied and the effect of overexpression or overstimulation of
this kinase in the parasite is still currently unknown. When Pfmap1 was heterologously
expressed in COS-7 cells, the expression of the wild-type version induced apoptosis in
those cells while a mutant in the phosphorylated TXY motif did not affect the cell growth
(12). MAPK over-activation in eukaryotic cells can lead to disease in humans and
aberrant changes in the growth and phenotype of a cell (5). Further investigation into
Pfamp1, PfMKP1, and other enzymes in the pathway may elucidate functions for the
MAPK pathway in the parasite.
The MAPK pathway is important in eukaryotic cells for cell function, growth, and
differentiation. The MAPK pathway plays a crucial role in the development of human
cancer and is of great interest as a drug target, for which there is already one drug
currently being used in the clinical setting (13). Based on our data presented here and
previously reported results, we propose a hypothetical MAPK pathway in P. falciparum
where PfMKP1 acts a MAPK phosphatase in the cytosol of the parasite (Fig. 3.6)
controlling the activation of Pfmap1. Filling in the gaps within this model could lead to
new targets for drug discovery in malaria.
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Figure 3.1: Domain Architecture of PfMKP1 and Recombinant Proteins Used in
Study. (A) PfMKP1 consists of an inactive rhodanese (RHD) domain followed by a
dual-specificity phosphatase (DUSP) domain similar to a Type II MAPK phosphatase
(MKP) where the inactive RHD domain acts as a MAPK binding domain (MKB). (B)
Recombinant protein constructs made for this study. GST fusion proteins, PfMKP1
(RHD, DUSP, RHD + DUSP) and PfYVH1, and His6 -tag (black bar) proteins, Pfmap1,
Pfamp2, and NusA. (C) Conserved active motif CX5R in human MKP3 and the atypical
motif found in PfMKP1. Site-directed mutagenesis of putative critical residues in the
DUSP domain of PfMKP1 are shown in bold.
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Table 3.1: Constructs Made in this Study for Production of Recombinant Protein.
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Figure 3.2: Recombinant PfMKP1 has Phosphatase Activity. (A) Phosphatase
activity was present in DUSP, DUSP C383A, full-length (RHD+DUSP), and YVH1 in a
pNPP generic substrate phosphatase activity. (B) DUSP C383A demonstrated higher
activity than DUSP, full-length PfMKP1, and YVH1 in a generic peptide-based (FDP)
phosphatase assay.
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Figure 3.3: PfMKP1 Interacts with Pfmap1. (A) A pull-down using Pfmap1 and 2 (or
NusA) as bait protein and recombinant PfMKP1 RHD (R), DUSP (D), or the full-length
protein (RD) as prey. A western blot using anti-GST illustrates the binding of bait and
prey proteins. (B) nLC-MS/MS analysis of parasite proteins bound to recombinant
PfMKP1 full-length construct (RHD+DUSP) or GST control. The table indicates number
of spectra associated with the protein identified by nLC-MS/MS and the p-value
(Fisher’s exact test) indicates significant enrichment in the full-length PfMKP1 sample.
All proteins were identified at 95% protein identification probability score. PlasmoDB ID
(v.11.0, www.plasmodb.org/).
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Figure 3.4: In vivo Expression and Phosphorylation of Pfmap1 in P. falciparum
NF54 Wild-type, C9 Mutant, and Complemented (Comp) Mutant. (A)
Phosphorylation status of Pfmap1 TXY motif (anti-pTpY; top panel) and overall
expression of Pfmap1 (middle panel) throughout the life cycle. Anti-PyBiP was used as
a loading control. (B) Densitometry of the bands shown in (A). Graph on left shows
densitometry units as measured and graph on right shows the percent of
phosphorylated Pfmap1 (units of anti-pTpY/units of Pfmap1 x 100).
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Figure 3.5: Changes in Pfamp1 Localization in P. falciparum C9 Mutant. Infected
RBCs (NF54 wild-type, C9 mutant, and C9 complemented mutant) were harvested ~28
hours post-infection and subjected to immunofluorescence assay using anti-Pfamp1
and Hoechst for nuclear visualization.

90

Figure 3.6: Simplified Schematic of Hypothetical MAPK Pathway in P. falciparum.
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CHAPTER FOUR:
DEVELOPMENT OF A MULTIPLE REACTION MONITORING ASSAY FOR
TRACKING THE ACTIVATION OF THE MAPK PATHWAY IN PLASMDOIUM
FALCIPARUM

Introduction
Mitogen-activated protein kinase (MAPK) pathways play important roles in
eukaryotic cellular response to external stimuli (4, 13). Once a signal is transmitted
through the cellular membrane, MAPKs (such as ERK, JNK, or p38 within human cells)
are activated by the phosphorylation cascade and affect overall transcription of the cell.
Mitogens (growth factors) were originally found to be activators of this pathway but other
signaling molecules such as pheromones and stress-inducing substances can also turn
on this pathway (4). MAPKs contain a conserved TXY motif that is phosphorylated by
an upstream kinase when the pathway is activated from on outside stimuli (3). In an
activated state, both residues (Thr, Tyr) must be phosphorylated in order for the kinase
to bind the appropriate substrate. This phosphorylation event specifically determines
the active state of the kinase.
Plasmodium falciparum is an intracellular human parasite that is of great public
health importance as it causes close to 1 million deaths per year worldwide (7). There
are two MAPKs in the P. falciparum genome. Pfmap2 is an atypical MAPK with a
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signature TSH motif and has been shown to be critical to the parasite life cycle (5, 6).
Pfmap1 is a typical MAPK which contains a canonical TDY motif that has been shown
to be necessary for catalytic activity in vitro (8).

Pfmap1 can be knocked-out and

parasite growth can continue in the erythrocyte in in vitro culture (5). However, the
effects of overexpression or over-activation of this kinase have not yet been studied.
Pfamp1 is most closely related to the human homologue ERK2 which is involved
in cell growth, differentiation, adhesion, and cytoskeletal rearrangement (2). However,
because P. falciparum has only 2 MAPKs compared to a much expanded MAPK family
in humans, Pfamp1 may take on extra roles within the cell and may also act in stress
response. Stressors may have different phenotypic effects on the parasite such as
dormancy or gametocytogenesis for which the mechanism of each is still unknown in
Plasmodium. Therefore, it is possible that Pfmap1 activation could act as a reporter for
cellular stress triggered by events such as drug pressure, osmotic pressure, waste
exchange or other environmental conditions.
Multiple reaction monitoring (MRM) utilizes retention time and mass-to-charge
ratio selectivity of peptides to robustly quantify proteins without labeling (1). MRM has
been used to successfully determine the stoichiometry of phosphorylated proteins in
organisms including yeast, mice, and human cells (1, 10, 11). An MRM workflow can
allow for the relative quantification of phosphorylated versus non-phosphorylated protein
in treated versus untreated cultures. In this work, we describe a novel MRM method to
monitor the phosphorylation status of Pfmap1 in P. falciparum.
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Methods

AQUA Peptides for Assay
Pfmap1 has been previously characterized and the activation motif TDY has
been identified as dually phosphorylated in previous phosphoproteome analyses of
Plasmodium falciparum (12).

In order to monitor the phosphorylation status of this

motif, the tryptic peptide was determined based on in silico digestion of the protein
sequence (taken from PlasmoDB v.11.0; www.plasmodb.org/). All phospho-variations
of this peptide were chosen for quantification (Table 4.1). In addition, two peptides for
overall quantification of the protein were chosen using Skyline© (64 bit, v. 1.3.0.3735,
University of Washington) with the following criteria: no Cys, His, Met, NXS/T, RP/KP, or
missed cleavages. Resulting peptides were tested for uniqueness against a merged
database of Plasmodium-human protein sequences obtained from UniProt. Based on
this criterion, two peptides were chosen for synthesis (Table).

All peptides were

synthesized by ThermoFisher Scientific as HeavyPeptideTM AQUA Basic peptides with a
heavy Arg residue (13C6; 15N4) with the exception of GAYGVVFK which had a heavy
Lys residue (13C6; 15N2). All peptides were rehydrated in water and stored at -20 C in
aliquots.

Multiple Reaction Monitoring (MRM) Methods Development
The top three MRM transitions from each AQUA peptide’s precursor mass-tocharge ratio (m/z) were determined via syringe-pump infusion in the tune mode of a
triple quadrupole mass spectrometer (TSQ Quantum Ultra, Thermo). Ion transmission
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optics for both precursor and product ions and product collision energies were optimized
in this mode as well. Product ions were determined empirically for the heavy-labeled
AQUA peptides and deduced for the unlabeled native peptides based on the loss of 8
(Lys) or 10 (Arg) for all Y ions (Table).
To determine the limit of detection (LOD) and limit of quantification (LOQ) for
each peptide standard, five microliter injections of mixed serially diluted AQUA peptides
(25-5000 fmol) were separated by reverse-phase HPLC on an Eksigent NanoLC 2D
Ultra system (Dublin, CA, USA) using an analytical column (ProteoPep II™ 75 μm
i.d. × 10 cm C18) manufactured by New Objective (Woburn, MA, USA) before subjected
to MS/MS. The mobile phase flow-rate was 350 nL/min and followed a linear gradient of
0-30 min 0-55% B (mobile phase A = 0.1% FA in water and B = 0.1% FA in acetonitrile).

Recombinant Pfmap1 Production and LC-MS/MS Analysis
Pfmap1 containing plasmid was a gift from Isabelle Lucet.

The cloning and

production of protein is outlined in Chapter 3 methods. Purified recombinant Pfmap1
was diluted 1:2 in a series and subjected to SDS-PAGE on a 10% Tris-Glycine gel. The
gel was stained with coomassie and destained. The subsequent Pfmap1 band (Fig.
4.3A) was cut from the gel and washed with acetonitrile to remove SDS. The gel slice
was then subjected to reduction, alkylation, and trypsin (Promega) digestion.

The

digested protein was extracted from the gel with acetonitrile and formic acid, speed
vacuumed to dryness and resuspended in 0.1% formic acid for mass spec analysis.
The resulting peptides were automatically injected using an autosampler into a reverse
phase nano-HPLC followed by triple quadrupole MS/MS as described above.
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RESULTS

Development of Assay Using AQUA Peptides
Mass transitions of AQUA peptides were determined by single peptide direct
infusions into the triple quad MS. Transitions were chosen based on uniqueness to the
given peptide. The precursors and transitions monitored for each AQUA peptide are
listed in the Table 4.1. Because the target peptide only differed in phosphorylation of
residues, transitions overlapped and only one product ion m/z was unique for individual
peptides.

However, given different retention times (Fig. 4.1) of the peptides and

different parent ion m/z (for most), peptides could be individually monitored. The LOQ
was determined for four of seven AQUA peptides (Fig. 4.2). Unphosphorylated peptide,
control peptides, and the singly phosphorylated tyrosine peptide were detectable
starting at 200 fmol. However, the other phosphorylated peptides were not detectable
even in the 1-5 pmol range and therefore the LOD and LOQ could not be determined.

MRM Assay Using Recombinant Pfmap1
Recombinant Pfmap1 was expressed as described previously (Chapter 3
methods). The recombinant protein was diluted 1:2 in a series and subjected to SDSPAGE.

The purified protein bands (Fig. 4.3A) were excised and run through nLC-

MS/MS on a triple quadrupole MS using the transitions developed with the AQUA
peptides.

Pfmap1

recombinant

protein

was

robustly

detected

using

the

unphosphorylated target peptide and the control peptides for total protein quantification
(Fig. 4.3B) even when small amounts were noticeable on the gel.

98

Discussion
Here within, we describe a novel method for the robust quantification of
phosphorylated Pfmap1 in Plasmodium falciparum blood-stage cultures.

Pfmap1

phosphorylation activates the kinase which may play an important role in the cellular
response to stimuli whether mitogenic or stress-inducing. This method can be used to
track cellular effects due to drug treatment or other stress or growth signals on the cell.
However, this method needs more refinement in order to fully function as a screening
tool: 1) to identify the true limits of detection and limits of quantification of
phosphorylated peptides and 2) purification of native Pfmap1 that is unbiased to
phosphorylation status.
Attempts using unenriched parasite lysate to identify Pfmap1 in LC-MS/MS were
unsuccessful. P. falciparum NF54 proteins were extracted from 50-100 ml of a 10%
parasitemia culture in order to identify Pfmap1 phosphorylated and unphosphorylated
forms. The protein lysate was run on a SDS-PAGE gel where the lanes were cut into
10 fractions and in-gel digestion was performed.

The resulting peptides were run

through a linear ion trap (LTQ XL, Thermo) mass spectrometer with 90 minute
gradients. Despite multiple attempts at identifying Pfmap1 in unpurified protein lysate, it
was never detected in the resulting spectra.

Previously, Pfmap1 was found to be

processed during the P. falciparum erythrocytic life cycle (8) and may represent a
challenge in quantifying the active kinase form. An enrichment of Pfmap1 may reduce
the milieu of proteins and allow for identification of Pfmap1 as previously done through a
pull-down with interacting partners (Chapter 3) or through phosphoprotein enrichment
(12). However, the enrichment step should not be biased to the phosphorylation state.
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An endogenous tag of the gene would be able to provide an unbiased method for
purification. Another issue that was not originally considered was that in previous work
(unpublished) the peptide containing the TDY motif was found as a missed cleavage
(Lys precedes the Val). In order to minimize the presence of a missed cleavage, a
double digestion with trypsin and Lys-C enzyme may be utilized.
There have been previous publications using this method to determine the
phosphorylation status of MAPKs in yeast (9) and the method could be very robust at
detecting cellular changes due to stress however more work is needed to optimize
many of the conditions (i.e. protein ID, peptide ionization, and potential missed
cleavages). This method can be applied to determine what extracellular stimuli activate
the MAPK pathway by monitoring the phosphorylation status of the MAPK Pfmap1 TXY
motif (Fig. 4.4). Pfmap1 activation may have significant effects on the cell as seen in
the C9 mutant (See previous chapters). This screen could determine compounds that
cause stress and could lead to the identification of the mechanisms behind drug
resistance and gametocytogenesis in Plasmodium, two important phenomenon that are
critical for the control and treatment of this deadly disease. In addition, as the piggyBac
mutant library expands towards saturation, we can test mutant strains of putative
kinases and phosphatases to determine if they are upstream enzymes in the MAPK
pathway allowing for elucidation of the pathway. More work that looks at signaling
events could lead to a better understanding of the parasite biology and further
development of treatment methods.
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Table 4.1: AQUA Heavy Labeled Peptides Used in Multiple Reaction Monitoring
Experiment.

Lower case (t or y) indicates phosphorylated residue.
* indicates neutral loss ion (y-H3PO4)
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Figure 4.1: Retention Time of Representative AQUA Peptides in Reverse-Phase
Nano-LC/MS.
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Figure 4.2: Limit of Detection for AQUA Peptides. AQUA peptides were serially
diluted and run on a triple quadrupole mass spectrometer. Resulting areas under the
curves are shown here and the respective R-squared value indicating good linear
quantification in the fmol range.
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Figure 4.3: Pfmap1 Recombinant Protein Expression and Peptide Analysis Using
MRM. (A) Coomassie stained Tris-Glycine gel showing purified recombinant protein
Pfmap1 in a dilution series. (B) The protein bands in (A) were subjected to in-gel
digestion and nLC-MS/MS. Three peptides were used to monitor the amount of protein
in each sample. Numbers correlate bands on gel with nLC-MS/MS results.

104

Figure 4.4: Workflow for Multiple Reaction Monitoring (MRM) Experiment.
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CHAPTER FIVE:
CONCLUSIONS

Discussion

Development of Screen for Cytoadherence Phenotype in piggyBac Mutants
Cytoadherence is an important pathogenic mechanism that allows P. falciparum
to cause high mortality rates (1, 9). Within this work, we have given proof of principle
for a quantitative cytoadherence screen that can be scaled to test multiple P. falciparum
strains at a time. During the course of our screen, we found that insertions in genes
with ontologies in protein modification, nucleic acid metabolism, and other unknown
genes affect cytoadherence of the parasite. We found these groups enriched in both
those parasites that are increased in cytoadherence and those that are decreased
compared to the wild-type. We further found that individual exported proteins did not
affect overall cytoadherence of the cell. A caveat to this is some mutants that have
undergone antigenic switching to another var gene in culture demonstrated decreased
binding to CD36. In these mutants, it cannot be verified as a defect in binding due to
the transposon insertion in a gene or due to the antigen switching. It is interesting to
note that some mutants in which the var gene expression switched had transposons
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inserted upstream of the original var gene which may have contributed to the cause of
the switch in expression.
A similar screen was designed for use in screening compounds to look for
inhibition of iRBCs bound to receptor CSA, which is involved in placental malaria (12).
An advantage to our screen is that we do not have a proprietary formula and are giving
free access to other researchers to use our methods. Both approaches use similar
image-based methods, however they differ in the analysis and calculations. Although it
was not directly tested, there is no reason to believe that these approaches cannot be
substituted for each other as both approaches were shown to reliably quantify a wildtype parasite dilution series (Chapter 2, (12)).

Further Characterization of PfMKP1
Previously

we

described

an

atypical

mitogen-activated

protein

kinase

phosphatase (MKP) in the Plasmodium falciparum genome as involved in control of cell
cycle timing (2).

Within this work, PfMKP1 was characterized further both

phenotypically and biochemically. We found that the piggyBac insertional mutant C9
eliminated expression of PfMKP1 and demonstrated increased cytoadherence due to an
increase of knobs on the surface of the iRBC (Chapter 2). Although we could not
determine how PfMKP1 directly affected the number of knobs on the surface, we
hypothesize that PfMKP1 is an important phosphatase that controls phosphorylation
within the protein export pathway. Further work will need to be done to determine the
global change in phosphorylation of the C9 mutant versus the wild-type to further
explore this hypothesis.
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We also found that although PfMKP1 has an altered CX5R motif it retains
catalytic ability and evidence suggests it uses Pfmap1 as at least one of its substrates.
This places PfMKP1 as a newly identified enzyme in the hypothetical MAPK pathway of
P. falciparum. This pathway is not fully known to exist in P. falciparum or in other
parasitic protozoan, however all eukaryotes from yeast to humans possess this pathway
in some form and it is likely that it also exists in Plasmodium species. The complication
in determining enzymes in the pathway is due to P. falciparum’s AT-rich genome and its
divergent protein sequences that do not allow for easy identification of homologues.
Experimental and bioinformatics analysis of hypothetical proteins in this pathway (Fig.
5.1) has led to the identification of kinases and phosphatases that can act in this
pathway however more empirical evidence is needed to support the existence of this
pathway.

Looking Forward

Mitogen Activated Protein Kinase Pathway
The existence of the MAPK pathway in P. falciparum could have a significant
impact on the biology of the parasite and the way we treat and control parasite
infections.

Recently, a MAPK inhibitor was found to inhibit P. falciparum cell growth

(5). In order to fully define the pathway, proteins must be identified including receptor
proteins that transmit the signal to the inside of the cell and the activators and
deactivators of the pathway.

Importantly, MAPKs traditionally translocate into the

nucleus where they interact with transcription factors to affect transcription.
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Determining the transcription factors that interact with MAPKs could lead to
identification of target genes of this pathway. The ApiAP2 transcription factors have
recently received attention for their involvement in important cellular regulation (13). In
mammalian cells, MAPKs can control both the expression of AP-2 transcription factors
and the binding of AP-2’s to DNA (11, 19).

Although ApiAP2’s are divergent from

mammalian and closer to plant AP2 transcription factors (13), they are still involved in
transcriptional regulation and their activators and repressors are currently unknown.
MAPK pathways can be turned on by both abiotic and biotic factors that can
contribute to stress response, cell differentiation, and cell growth (7, 14, 20).

Cell

differentiation and cell cycle is under tight control in Plasmodium where it must undergo
the proper differentiation within the proper environment (3, 4). Turning on genes for
sexual development in the hepatocyte of the host could lead to inhibition of parasite
growth. Turning on genes in the red blood cell that are involved in exflagellation of the
parasite could again lead to inhibition of cell growth. Therefore, the parasite must be
able to sense its host environment and respond properly by turning on the correct set of
developmental genes. Since 1979, it has been known that gametocytes in a laboratory
setting respond to the use of “spent” media meaning media that contains waste
products of parasites grown asexually in vitro (6 LH, 1979). This practice illustrates that
there is an accumulation of waste product(s) that signal the cell to differentiate sexually
instead of continuing on the default asexual pathway further indicating that the parasite
responds to stimuli in the external environment.
In addition, a phenomenon that is growing in acceptance is the observation that
when parasites in the erythrocytic cycle are exposed to drugs, such as artemisinin, they
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form an environmentally resistant, reduced metabolic state that does not continue to
progress through the cell cycle until the drug pressure is relieved (8, 10, 15, 16, 18).
This “dormant” form could be the result of a stress response pathway in the parasite in
which transcription is inhibited through a negative feedback loop. Notably, in human
cancer cells treated with artemisinin, the cell stops its progression in the cell cycle in the
G1 or G2/M phase (17, 21).
Other eukaryotic cellular responses to stress are mediated by the MAPK pathway
such as osmotic pressure, hydrogen peroxide exposure, and temperature aberrations
(14). To further determine the cellular mechanism for stress pathways in P. falciparum,
monitoring the activation of the MAPK pathway could lead to informative insights on the
parasite’s ability to sense its external environment and respond. Based on the results
published in this work, screens for monitoring Pfmap1 activation are proposed.

Screens for MAPK Pathway
In order to monitor Pfmap1 and its activation state, two biological aspects can be
considered: 1) activation of the TXY motif through phosphorylation and 2) translocation
of the protein into the nucleus.
Screen one: monitoring Pfmap1 phosphorylation. MAPKs are activated by
phosphorylation of the TXY motif. When activated, the MAPK will translocate into the
nucleus to affect cell transcription. Chapter 4 described the development of a multiple
reaction monitoring (MRM) method for robust relative quantification of the TXY
phosphorylation state of this motif on Pfmap1. Unfortunately, this method has not come
to full fruition and still needs experimental development to become a working assay.
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However, this assay could monitor Pfmap1 status in related mutants to determine if
other enzymes are acting in this pathway.

For example, sorbitol allows for

synchronization of intra-erythrocytic cultures but its mechanism is not fully understood. It
is possible that it causes osmotic stress signaling to the cell in only specific
developmental stages which may be regulated by Pfmap1. In addition, cultures could
be treated with varying substances and screened for activation of this pathway including
drug treatment, ex. artemisinin.
Screen two: Pfmap1 translocation within the cell. A robust method for the
localization of Pfmap1 can be useful in determining the active state of the MAPK
pathway within P. falciparum.

An immunofluorescence assay for Pfmap1 was

described in Chapter 3 using rabbit anti-Pfmap1. To scale up this assay, the Operetta
HCS can be used to determine localization within many parasites under varying
conditions. A cytoplasmic marker should be used in addition to the nuclear stain in
order to provide appropriate contrast for proper analysis by Harmony software.
Determination of the translocation of Pfmap1 to the nucleus will aid in the ability to
detect the activation state of the pathway in the cell and the kinase’s effect on
transcription that lead to changes in parasite phenotype. These two screens together
can provide further proof of the MAPK pathway and its role in cellular development.

112

Figure 5.1: A Hypothetical MAPK Pathway in Plasmodium falciparum.
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APPENDIX A:
FURTHER CHARACTERIZATION OF PFEMP1 IN C9 MUTANT

Methods

RNA Isolation, cDNA Synthesis, and Quantitative Reverse Transcription
(qRT)-PCR
RNA was isolated and purified using a TRIzol reagent and following
manufacturer’s directions (Invitrogen). First-strand cDNA was synthesized by random
primer mixes using Superscript III Reverse Transcriptase (Life Technologies) according
to the product manual. PCR primers used for detecting mRNA expression of var genes
were as described previously (1). qPCR was performed on a Stratagene Mx300P. The
relative standard curve method (ABI User Bulletin #2) was used where genomic DNA
was used in a standard curve to determine relative copy number and a housekeeping
gene

seryl-tRNA

synthetase

(PF3D7_0717700)

was

used

to

normalize

the

transcriptional level of each var gene. Parasite RNA was first subjected to degenerate
primers that identified a group or family of var genes for which individual var genes
could be tested for. See Table A.1 for primer sequences.
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Immunoflourescence Assay (IFA)
Parasites

were

synchronized

as

stated

previously

(Chapter

2)

and

immunofluorescence assays were done as previously described (2). Blood films were
double-stained with Rabbit anti-Pf332 mAb51-22 diluted 1:500 followed by TRITCconjugated Goat anti-rabbit secondary (1:1000) and Guinea pig anti-ATS sera diluted
1:500 followed by FITC conjugated goat anti-guinea pig secondary (1:1000) (anti-Pf332
and anti-ATS sera were kind gifts of Denise Mattei). Nuclei were stained with 0.2 mg/ml
4′, 6-diamidino-2-phenylindole (DAPI; Molecular Probes). Parasites were visualized by a
DeltaVision CORE microscope (Applied Precision).

Results

var Gene Expression Remains Stable
We found that P. falciparum NF54, P. falciparum NF54 helper (contains
transposase episome), and C9 mutant line expressed a var gene that reacted with
primers in the BC1 and BC2 group (Fig. A.1A). Since these are degenerate primers,
overlap is expected. Based on the grouping BC1/BC2, individual var gene expression
was tested for with primer pairs that recognized specific var genes (see table). Of the
25 different var genes that were tested for, only the 9ʹ primer pair gave distinct results
for both NF54 wild-type and C9 mutant (Fig. A.1B). However, none of the 25 primer
sets tested identified the correct var gene expressed in the helper line. Moving forward
with the cytoadherence screen, the helper line was no longer used due to the change in
var gene expression. Based on these results, all piggyBac mutant lines used in the
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cytoadherence screen (Chapter 2) were tested for var gene expression using the 9ʹ
primer set which correlates to gene ID: PF3D7_0421100.

Further Study of PfEMP1 in C9 Mutant
Due to the change in cytoadherence phenotype (see Chapter 2) in the C9 mutant
line, we investigated the surface expression of PfEMP1 through western blot (Chapter
2) and IFA (Fig. A.2).

In the IFA, PfEMP1 was found to associate with Pf332 (a

Maurer’s cleft marker) and in punctate spots on the surface of the iRBC as expected.
There was no apparent increase in PfEMP1 surface expression.
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Table A.1: var Gene Primers Used in Study.
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Figure A.1: Determination of var Gene Expression in P. falciparum Strains. (A) The
var gene group was first tested using degenerate primers and then the var gene within
the group was determined for each strain (B).
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Figure A.2: Immunofluorescence of P. falciparum C9 Mutant Proteins Involved in Cytoadherence.
Maurer’s cleft marker protein, PfEMP1 = Erythrocyte membrane protein 1, DAPI = nuclei stain.
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APPENDIX B:
CHARACTERIZATION OF BINDING SITES IN PFMAP1 AND PFMKP1 AND
PROPOSED SITE-DIRECTED MUTAGENESIS

Methods

Homology Modeling of Pfmap1
Pfmap1 protein sequence was retrieved from PlasmoDB v11.0 (gene ID:
PF3D7_1431500).

The entire sequence was submitted to Swiss-Model Template

Identification (http://swissmodel.expasy.org/).

Results of the template identification

were used in Swiss-Model Workspace to create a homology model ([1, 2] Biasini, M. et
al., Manuscript in preparation). The model was viewed and edited using Pymol.v.1.10
(Schrodinger, 2010).

Rhodanese Domain Alignment
The sequence of PfMKP1 (PF3D7_1305500) and orthologous Plasmodium
sequences were retrieved from PlasmoDB v11.0 (www.plasmodb.org). Outlier species
were identified through BLAST searches with the rhodanese (RHD) domain using NCBI
BLASTP. Sequences with the greatest homology to the PF3D7_1305500 ORF were
retrieved and used to build the multiple alignment using ClustalW (3, 5).
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Site-Directed Mutagenesis of PfMKP1 RHD Domain
Plasmid containing E. coli codon optimized PfMKP1 RHD sequence (see
Chapter 3 methods) was used as the template. Primers were designed to mutagenize
the RHD domain (Table B.1) based on previous methods (6).

PCR was used to

mutagenize the template, followed by ligation of the plasmid and transformation into E.
coli DH5α (NEB). Antibiotic resistant clones were propagated in broth and subjected to
plasmid purification.

Plasmids were sent for sequencing to confirm mutations and

correct plasmids were subcloned into BL21 expression vector (NEB) and expressed
following methods outlined in Chapter 3.

Results

Conserved Sequences in Pfmap1
Template identification through Swiss-Model yielded Cryptosporidium parvum
MapK (PDB ID: 3oz6B) as the top hit. However, in order to compare to a well described
MAPK, for subsequent homology modeling the template for human ERK1/MAPK5 (PDB
ID: 2zoqB) was used. This template had an E value of 1e-67 compare to the E value of
C. parvum at e-109. Top hits also included the human MAPK p38 indicating homology
to more than one type of MAPK.
Previous reports have indicated the presence of the catalytically imperative TXY
motif in Pfmap1 (2, 4). Here we identify a putative common docking (CD) motif in the
homology model of Pfmap1 using ERK1 as a template (Fig. B.1). The CD motif usually
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consists of a DXXD motif (7). Pfmap1 has a SXXD (aa316-319) motif in the same
position as the CD motif (Fig. B.1).

Identification of a Putative Kinase Interaction Motif in PfMKP1
Comparison of the PfMKP1 RHD domain with other RHD domains identified a
conserved motif indicative of a kinase interaction motif (Fig. B.2). Typically, this motif is
arginine rich in other organisms where the arginine residues are critical for binding (1).
In P. falciparum, the AT-rich genome biases lysine residues therefore in the P.
falciparum sequence; lysine (K122, K123) takes the place of critical arginine. The KIM
motif is generally followed by a small stretch of hydrophobic amino acids which are
present in PfMKP1 RHD domain. Based on the alignment, we propose the KIM motif in
the RHD domain is residues 118-132.

Discussion
We have identified putative binding domains for both Pfmap1 and PfMKP1 that
demonstrate how they may interact. Further work is necessary to confirm the role of
these motifs in the binding interaction. Quantitative binding using the Octet ® (ForteBio)
platform will be used to assess the putative KIM residues using the site-directed
mutants. It is hypothesized that all mutants except K59A, K60A, which is a control
mutation, will show reduced binding to Pfmap1 in vitro.
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Table B.1: Primers Used for Site-Directed Mutagenesis of PfMKP1 Rhodanese
Domain.
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Figure B.1: Homology Model of Pfmap1 Based on ERK1 (2zoqB). Single asterisk
indicates putative Common Docking site (SIID) and double asterisk indicates TDY
active site.

126

Figure B.2: Identification and Mutagenesis of the Kinase Interaction Motif in
PfMKP1. (A) PfMKP1 has domains (RHD and DUSP) indicative of a Type II MKP (MKB
and DUSP) where there is a putative Kinase Interaction Motif (KIM) in the RHD domain.
(B) Rhoadnese domain of PfMKP1 aligned with orthologues in Plasmodia and other
organisms. (Pf= Plasmodium falciparum, Pv = Plasmodium vivax, Pk = Plasmodium
knowlesi, Pb = Plasmodium berghei, Py = Plasmodium yoelli, Sc = Saccharomyces
cerevasiae, Sp = Schizosaccharomyces pombe, Dm = Drosophila melanogaster, Hs =
Homo sapiens). (C) Scheme for site-directed mutagenesis of KIM in PfMKP1 RHD
domain. KIM is underlined and boxed amino acids were mutated in SDM.
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